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An acapsular mutant of Cryptococcus neoformans was se¬ 
lected as a source of antigens to measure cell mediated immunity 
in infected guinea pigs so that interference from the capsular 
polysaccharide could be minimized. Yeast cells were mechanic¬ 
ally disrupted and the postmitochondrial supernatant was cen¬ 
trifuged at 105,000 x g. The soluble supernatant (105K) and a 
microsomal fraction were used as skin test antigens and as 
stimulants of in vitro lymphocyte blastogenesis. Polyacryl¬ 
amide gel electrophoresis revealed two major proteins in the 
microsomal fraction (JKB) and seven proteins in the 10 5K super¬ 
natant. Electron microscopy of the ios showed both membranes and 
ribosomes. Normal guinea pigs and those infected with C. 
neoformans were skin tested weekly for a period of 6 weeks. The 
highest 24 hr cutaneous immune responses were between the 3rd 
and 5th weeks. The 105K antigen was the most potent and gave 
vi 
2 
the highest reaction (32.1 mm ) at the 50 g dose after 24 hr, 
and the fraction elicited a moderately lower reaction on a 
weight basis than the other antigens tested at 24 hr. 
A simplified sensitization procedure for priming animals 
for lymphocyte blastogenesis consisted of a single dose of 
1 x 107 live cryptococci given intraperitoneally. Both the ps 
and 105K antigens elicited blastogenesis from peritoneal exu¬ 
date cells (PEC) and peripheral blood leukocytes (PBL) of 
infected animals. Maximal stimulation ratios were achieved 
with a dose range of 1 to 10/*g of antigen protein per ml and 
after 4 days of incubation. At the concentrations used, neither 
antigen was mitogenic nor toxic toward PEC or PBL. Splenocytes 
and lymphocytes from inguinal and popliteal nodes of infected 
and antigen-sensitized animals did not respond to either anti¬ 
gen in vitro. The basis for this is not known. Both splenocytes 
and lymph node cells responded vigorously to ConA. Pre¬ 
treatment of guinea pigs with cryptococcal polysaccharide two 
weeks prior to infection did not alter their in vitro lymphocyte 
responsiveness to the us and 105K antigens. 
In a typical experiment, 3 of 6 animals' PBL responded with 
stimulation ratios of 6.55, 21.1 , 35.42, to thesis and 1.41, 
9.33 , 17.39 to the 105K antigens at lyt/g/ml. Four of six 
animals' PEC responses were positive with stimulation ratios of 
2.62, 2.72, 4.02 and 7.20 toward ^s and 2.62, 5.13, 5.71, 10.01 
to 105K antigens at lyug/ml. Large animal-to-animal variations 
made it difficult to compare results between different experi¬ 
mental groups. When small capsule and large capsule isolates 
Vll 
were compared in infection studies, the small capsule form was 
not isolated from the brain in contrast to the isolated large 
capsule forms which were found in 2 of 3 animals. There were 
no differences in in vitro lymphocyte reactivity between these 
two groups. 
The specificity of the cryptococcal antigens was demon¬ 
strated in skin tests of guinea pigs sensitized with Histo- 
plasma capsulatum A811 (CDC) or Candida albicans 3181A (CDC). 
There was no crossreactivity in either group of animals. The 
us and 105K antigens appear to be potent and specific stimulants 
of delayed cutaneous hypersensitivity and in vitro lymphocyte 
blastogenesis in animals sensitized with neoformans. 
VI11 
ACKNOWLEDGMENTS 
I wish to express my sincere appreciation to all those who 
have given of themselves in the development and preparation of 
this dissertation. 
I am partially indebted to Dr. Errol Reiss of the Mycology 
Division, Center for Disease Control, Atlanta, Georgia, for his 
invaluable guidance and tireless assistance which proved to be 
the necessary ingredients to catalyze the production of this 
dissertation. I am just as indebted to each of my committee 
members: Dr. James Penn, Jr. (chairman), Dr. Lucille Tunstall, 
Dr. Roy Hunter, Jr. and Dr. John E. Mayfield. I would also like 
to express my sincere thanks to Dr. William Foege (Director, 
Center for Disease Control, Atlanta, Georgia) and Dr. Libero 
Ajello (Director of the Mycology Division, C.D.C.). I would 
also like to thank the animal caretakers, Mr. Horace L. Mayes 
and Mr. Robert K. Teart. 
Thanks to each of my family members for their continued 
support during undergraduate and graduate years and for pro¬ 
viding a wholesome family upbringing full of love and sin¬ 
cerity. 
IX 
LIST OF FIGURES 
Figure Page 
1. Flow diagram showing preparation of 
microsomal fractions from neoformans. . 25 
2. Antigen preparation scheme, continued . . 26 
3. Antigen preparation scheme, continued . . 27 
4. Mechanical disruption of C_^ neoformans 
0-3 min treatment  29 
5. Mechanical disruption of C^_ neoformans 
3-5 min treatment  30 
6. Diagram of the closed loop cell sonification 
system  32 
7. Elution profile of the postmitochondrial 
supernatant from C_^ neoformans B-551 ... 35 
8. Schematic diagram showing treatment sequence 
of the first 25 fractions eluted from the 
DEAE Sephadex column 36 
9. SDS-PAGE of £s and 105K antigens  48 
10. Molecular weight estimation of cryptococcal 
proteins 49 
11. Negative contrast electron microscopy of the 
|4S antigen 50 
12. Skin tests with the 105K antigen at the 50 
Hg dose 56 
13. Skin tests with the microsomal antigen (J\s) 
at the 50 M g dose 57 
14. Skin tests with the PMS antigen at the 50 
Hg dose   . . 58 
x 
LIST OF TABLES 
Table Page 
1. A schedule for injection of live yeast 
and subcellular antigens of C^_ neoformans 
in five guinea pigs 41 
2. Cutaneous reactivity in guinea pigs elicited 
by the Post Mitochondrial Supernatant of 
Cryptococcus neoformans 602 and of fraction 
prepared from it by DEAE Sephadex ion 
exchange chromatography  47 
3. Cutaneous reactivity in normal guinea pigs 
tested with subcellular fractions of 
Cryptococcus neoformans 602 and B551. . . 52 
4. Cutaneous reactivity in normal guinea pigs 
tested with Cryptococcus neoformans B551 
and further tested with subcellular frac¬ 
tions of C^ neoformans B-551 and 602. ... 53 
5. Cutaneous reactivity in guinea pigs sensi¬ 
tized with live Cryptococcus neoformans 
and further tested with subcellular fractions 
of Cryptococcus neoformans B-551 and 602 . 55 
6. (Expt. 118) Lymphocyte blastogenesis of 
peritoneal exudate cells elicited in 
vitro by subcellular fractions of C_j_ neo¬ 
formans in guinea pigs primed by infection 
and skin testing 60 
7. (Expt. 118) Lymphocyte blastogenesis of 
spleen cells elicited in vitro by subcellular 
fractions of C^_ neoformans in guinea pigs 
primed by infection and skin testing ... 62 
8. (Expt. 118) Lymphocyte blastogenesis of 
lymph node cells elicited in vitro by 
subcellular fractions of C^_ neoformans in 
guinea pigs primed by infection and skin 
testing 64 
9. (Expt. 118) Lymphocyte blastogenesis (S/C) of 
lymph node cells elicited in vitro by con A as 
a function of age, culture, source of lympho¬ 
cytes and presence of serum supplement in the 
medium  66 
xi 
LIST OF TABLES CONTINUED 
Table Page 
10. (Expt. 118) Lymphocyte blastogenesis (S/C 
of spleen cells elicited in vitro by con A 
as a function of age of culture, source of 
lymphocytes and presence of serum supplement 
in the medium  67 
11. (Expt. 119) Lymphocyte blastogenesis of 
peritoneal exudate cells elicited in 
vitro by subcellular fractions of C^_ neo- 
formans in guinea pigs primed by infection 
and skin testing  69 
12. (Expt. 119) Lymphocyte blastogenesis of spleen 
cells elicited in vitro by subcellular frac¬ 
tions of C^_ neoformans in guinea pigs pre¬ 
treated with capsular polysaccharide prior 
to infection and skin testing  71 
13. (Expt. 119) Lymphocyte blastogenesis of 
peripheral blood lymphocytes elicited in 
vitro by subcellular fractions of C. 
neoformans in guinea pigs primed by 
infection and skin testing  73 
14. Lymphocyte blastogenesis elicited by 
microsomal and soluble cytoplasmic 
antigens in guinea pigs infected with 
small capsule Cryptococcus neo¬ 
formans B551  76 
15. Lymphocyte blastogenesis elicited by 
microsomal and soluble cytoplasmic 
antigens in guinea pigs infected with 
large capsule Cryptococcus neoformans 




The yeast, Cryptococcus neoformans (C. neoformans), is 
found widely distributed throughout the world and causes the 
disease cryptococcal meningitis. It is believed that this 
infection occurs after inhalation of dust that contains viable 
yeast in association with pigeon droppings from rural and urban 
enviroments. The extent of subclinical exposure in the general 
population remains unsubstantiated, due to the lack of an 
effective skin test antigen. Although fungal diseases are not 
reported through an organized system, there were 338 confirmed 
human cases of cryptococcal meningitis in the United States in 
1976 (Kaufman and Blumer, 1977) and the number of such cases has 
been rising, due to improvements in laboratory diagnosis and an 
increased awareness on the part of physicians. Since the role 
of cell mediated immunity is not well defined for this disease, 
the objectives of the present research were to prepare a skin 
test antigen from C^ neoformans and to adapt it for the 
lymphocyte blastogenesis assay, using various lymphoid popula¬ 
tions from infected animals. The ability of subcellular 
fractions of neoformans to elicit blastogénie responses in 
infected animals could give clues about the role of cell 
mediated immunity in infections due to this yeast. 
1 
CHAPTER II 
REVIEW OF LITERATURE 
Mycology and taxonomy 
C. neoformans is an encapsulated yeast that reproduces by 
multipolar budding, sometimes producing several buds simul¬ 
taneously. The buds are attached to the parent cell by a thin 
wall and narrow pore. Under conditions of rapid growth, the 
buds break free of the parent cell precociously, and the cells 
found in tissue and in culture vary widely from 4 to 20yum in 
diameter. This yeast is surrounded by a mucoid polysaccharide 
capsule, which may vary from less than 2 jj m in thickness to 4 m 
(Staib et al., 1977) depending on the isolate. Usually the 
capsule thickness is greater in tissue than in culture (Emmons 
et al. , 1977) . C_^ neoformans was first isolated by Sanfelice 
(1894) from fruit juice, and later it was found in milk (Carter 
and Young, 1950), where it may have been a contaminant from 
utensils, since there was no evidence of illness in the cows. 
Emmons (1951) located C^ neoformans in soil in Virginia and 
later (Emmons, 1955) reported that this pathogenic yeast was 
found abundantly in the nests and accumulated droppings of 
pigeons. 
Kwon-Chung (1976) discovered compatible mating types 
among C^ neoformans isolates that completed a basidiomycetous 
sexual cycle. The perfect state, Filobasidiella neoformans, 
is produced by compatible A and D serotype isolates whereas a 
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separate species, E\_ bacillispora, is found among mating cul¬ 
tures of B and C serotypes. E\_ bacillispora differs from F. 
neoformans by its slender bacilliform sexual spores. Mating 
experiments between serotype A of neoformans and either B or 
C serotypes yielded limited amounts of mycelia with or without 
clamp connections, but this rudimentary mycelium failed to 
complete the sexual reproductive cycle. The clamp connections 
were incomplete and failed to fuse with adjacent hyphae. 
However, the existence of two mating types among B or C 
serotypes was indicated by the observation that isolates of B 
and C types produced hyphae and a basidium thus providing 
evidence for F^ bacillspora (Kwon-Chung, 1976). 
Ecology 
C. neoformans causes disease in human beings. This yeast 
is widely distributed throughout the world in rural and urban 
areas. Like most other systemic mycoses, it is not contagious 
and there is no evidence of its direct transmission from human 
being to human being. The disease may be either acute or 
chronic, and the portal of entry is the lung. Dissemination may 
occur especially to the brain, but also to the joints, bones, 
eyes and skin. 
C. neoformans infections occur after inhalation of dust 
that contains viable yeast from rural environments such as 
barns, attics and towers, as well as urban pigeon roosting 
sites. It is believed that workers, who are exposed to pigeon 
droppings during the demolition of old buildings, may be more 
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susceptible to cryptococcosis (Emmons, 1955). This remains 
unsubstantiated for the lack of an effective skin test to detect 
the extent of subclinical exposure. 
Epidemology 
Although fungal diseases are not reported through an 
organized system, the data compiled by Kaufman and Blumer 
(1978) at the Center for Disease Control (C.D.C.) showed an 
annual increase in C^ neoformans infections in which C.D.C. 
aided in the diagnosis. Over a period of four years, cases 
increased from 250 in 1973 to 338 in 1976. The 338 cases were 
confirmed human cases of meningitis, originating in the United 
States. The increased number of infections probably reflects 
improved diagnostic techniques, an increased awareness on the 
part of the physicians, and also a true increase, due to the 
observation that about half of the infected persons had some 
underlying immunodeficiency. 
Pathogenesis 
After inhalation of viable yeast, a local pulmonary in¬ 
fection develops. The occasional finding of C^ neoformans in 
solitary nodules in the lungs of persons without progressive 
cryptococcosis, demonstration of pulmonary lesions in some 
cases of meningeal cryptococcosis, and the known importance of 
respiratory infection in other mycoses, make it probable that 
cryptococcosis is a pulmonary disease with hematogenous spread 
to skin, bones, abdominal viscera and specially to the central 
nervous system. This concept recognizes the transitory nature 
of the pulmonary lesion which either heals by encapsulation 
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leaving a "cryptococcoma", heals without leaving any residue, 
or is so insignificant that it is not found in many fatal cases 
of cryptococcal meningitis. Hasenclever and Emmons (1963) 
demonstrated a similar pattern of pathogenesis in mice experi¬ 
mentally infected by the intravenous injection of neo- 
formans. 
Another factor that makes the diagnosis difficult is that 
enlarging cerebral lesions have the radiologic appearance of a 
growing neoplasm or granuloma. As a result nearly one-fourth 
of patients with central nervous system cryptococcosis have had 
a neurosurgical procedure performed before the correct diagno¬ 
sis was known (Rippon, 1974). 
In some cases, the pulmonary disease itself may increase 
sufficiently to cause death, but more often, dissemination 
occurs to the central nervous system. The yeast is eliminated 
from most internal organs of the body, but by using the 
circulatory system as a transport vehicle, it can cross the 
blood-brain barrier. Once the yeast has seeded the cerebro¬ 
spinal fluid, it is distributed by the cerebral circulation to 
the surfaces of the brain and spinal cord (Littman, 1958). In 
the central nervous system, the subarachnoid space, a delicate 
fibrous membrane covering the brain and spinal cord, is often 
distended by gelatinous clusters of yeast cells resembling tiny 
soap bubbles, particularly over the base of the brain and in the 
region of the cerebellum. Cystic masses occur in the gray 
matter, sometimes near the surface or deep in the basal ganglia 
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or the pons. The spinal meninges are often involved, but rarely 
the spinal cord itself. Lesions of cryptococcosis are usually 
characterized by mildness of the host's inflammatory response 
to the invading fungi; sometimes there is none at all, espe¬ 
cially in brain involvement (Wilson and Plunkett, 1965) . 
Histopathologically, the yeast cells are seen mostly in 
small, individual, roughly circular, clear spaces, formerly 
thought to be due to the histolytic ability of the organism, but 
now known to result from the presence of the characteristic 
capsule. The capsular substance is either collapsed during the 
process of fixation, sectioning and staining, or is converted 
into a few shrunken strands radiating outward from the yeast 
cells. 
Cryptococcal Meningitis in Immunologically 
Compromised Hosts 
It was reported that C_^ neoformans acts as an opportunist 
in renal transplant patients. Schroeter et al. (1976) re¬ 
ported ten cases of meningitis out of 650 renal transplants over 
a 13 year period. This group consisted of eight men, one woman 
and one 12 year old girl. During treatment of these particular 
renal patients, it was discovered that each had an underlying 
case of cryptococcal meningitis. At the time of diagnosis, all 
patients were receiving maintenance regimens of the immuno- 
suppressant drugs, prednisone and azathioprine. Drugs were 
used as a reserve for rejection crises of renal transplants, but 
at the same time, the host became vulnerable to the opportunist 
fungus. The central nervous system was affected in nine 
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patients; there was meningitis in eight; and a brain granuloma 
in one patient. Three of these patients received more than one 
renal transplant before the diagnosis of cryptococcal menin¬ 
gitis. In eight patients, the infection appeared after long¬ 
term immunosuppression, during the third to the tenth year 
after transplantation. In the other two patients, the diag¬ 
nosis was made during the fourth and the tenth months after 
transplantation. The common symptom of the central nervous 
system infection was headache, which occurred in eight out of 
nine patients. 
There is now ample evidence that neoformans dissemi¬ 
nates to involve the skin (Schupbach et al., 1976). Five 
patients with the following primary diseases developed derma¬ 
tological symptoms: a 74 year old man with chronic lymphocytic 
leukemia, two women (48 and 65 years old) with lupus erythe¬ 
matosus, a 35 year old woman with multiple myeloma, and a 17 
year old man with autoimmune hemolytic anemia. It was later 
discovered that each patient was suffering from a secondary 
infection with neoformans. With increasing awareness of 
cutaneous involvement, some cases of disseminated crypto¬ 
coccosis will be diagnosed sooner, leading to earlier therapy 
and improved prognosis. 
Capsular Polysaccharide as An Aggressin , 
Bulmer et al. (1967), studied the virulence of an acap- 
sular mutant C. neoformans. Seven acapsular mutants of C. 
neoformans were isolated from an encapsulated strain of human 
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origin. The mutants of the parent strain (CIA) were obtained 
by irradiating a suspension of cells with ultraviolet light. 
Initially, the mutants were avirulent for mice, but after 
several months of subculturing, six of the seven isolates 
reverted to the encapsulated state accompanied by a regaining 
of virulence. The results showed a positive correlation 
between the presence of capsule and virulence in C\ neoformans. 
This yeast is one of the few pathogenic fungi for which a 
virulence factor has been clearly identified. The binding of 
cryptococcal polysaccharide to an acapsular mutant of neo- 
formans was studied by Kozel (1977). Binding of purified 
polysaccharide to the yeast was determined by inhibition of 
phagocytosis and indirect immunofluorescence techniques. The 
ability of cryptococcal polysaccharide to prevent phagocytosis® 
of the capsular mutant appears to be directly related to 
adherence of polysaccharide to yeast by means of a specific 
receptor on the yeast cell surface. 
Bulmer and Sans (1968) showed that nonencapsulated crypt¬ 
ococci treated with cryptococcal polysaccharide can be washed 
with saline and remain partially resistant to phagocytosis. An 
experiment was done to confirm this observation and to deter¬ 
mine what effect cryptococcal polysaccharide might have on the 
phagocytic activity of the macrophages themselves. Yeast cells 
(3.3 x lO^/ml) in Hanks' Balanced Salt Solution (HBSS) were 
incubated for 30 min at 37 C with an equal volume of crypto¬ 
coccal polysaccharide (2 mg/ml in saline) and washed three 
9 
times with HBSS. Macrophage monolayers were also incubated for 
30 min at 37 C with cryptococcal polysaccharide at a final 
concentration of 1 mg/ml and washed three times with HBSS. 
Yeast cells and macrophages were incubated together for 2 hr at 
37 C and examined to determine the percent phagocytosis. In the 
absence of soluble polysaccharide, cells of acapsular C. neo- 
formans 602 were engulfed readily by macrophages. Treatment of 
macrophages with soluble polysaccharide had no effect on their 
ability to engulf the yeast. Examination of polysaccharide- 
treated macrophages by immunofluorescence techniques showed no 
observable polysaccharide adherent to the surface of the mac¬ 
rophages. Polysaccharide treatment of strain 602 signifi¬ 
cantly reduced the ability of macrophages to engulf the yeast 
and the percent phagocytosis was inhibited to the extent seen 
with the fully encapsulated strain 613. These results indicate 
that a receptor for polysaccharide occurs on the surface of the ) 
yeast cell wall and that once it is bound, polysaccharide 
inhibits the attachment phase of phagocytosis. 
Dykstra et al. (1977) used groups of 10 mice infected 
intravenously with 103, 103, 10^ or 10^ viable particles of 
large or small-capsule neoformans. As a rule, deaths 
occurred first among those animals given cells having smaller 
capsules. Once dying started, however, there was no difference 
in the rate of dying with respect to the size of the capsule at 
any of the dosages except the 103. At this dosage, cells of the 
mucoid culture appeared to be less virulent. Considering that 
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the difference observed could have been due to the smallness of 
the group size, a second experiment was undertaken, repeating 
the dose of 10^ but using 30 mice per group. With the larger 
number of animals, no disparity was seen; animals died at 
essentially the same rate, irrespective of whether cells in the 
inocula were thinly or thickly encapsulated. In all experi¬ 
ments, tissues of animals contained encapsulated cells, re¬ 
gardless of the condition of the inoculum. 
The meningococcus Neisseria meningitidis (N. meningi¬ 
tidis) is the cause of meningococcal septicemia and epidemic 
meningitis. Liu et al. (1971) reported the composition of 
Group A meningococcal capsular polysaccharide. It was a homo¬ 
polymer of D-mannosamine phosphate which was partially N- and 
O-acetylated. The principal glycosidic bond was a 1-6 phos- 
phodiester bond from the hemiacetal group of carbon 1 and the 
alcohol group of carbon 6 of the D-mannosamine. 
Polysaccharides were extracted from cultures of Nj_ men¬ 
ingitidis serogroups A and C high-molecular weight form. These 
polysaccharides are highly immunogenic in man (Gotschlich et 
al., 1969; Artenstein et al., 1971) and group C polysaccharide 
vaccines protect against disease in humans (Gold and S. Arten¬ 
stein, 1971). Gotschlich et al. (1969) showed that group B 
polysaccharide contains sialic acid as the major constituent 
(66.4%). Later Liu et al. (1971) showed the susceptibility of 
this polysaccharide to neuraminidase. In contrast, group C 
polysaccharide was found to contain 75% sialic acid and both 
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O-acetyl and N-acetyl groups. This polymer was resistant to 
digestion by neuraminidase (Liu et al., 1971). 
It appears that the pneumococcus (Streptococcus pneu¬ 
moniae) can survive and produce pneumonia and meningitis in the 
host primarily because of its capsule. Once a strain loses its 
capsule, it is readily phagocytized and destroyed (Volk, 1978) . 
Encapsulated Haemophilus influenzae (H. influenzae) 
type b is a primary pathogen producing nasopharyngitis and 
meningitis. Acute purulent meningitis occurs mostly in the age 
range from 2 months to 3 years. The restriction of these infec¬ 
tions to infants and the young children is probably related to 
the finding by Fothergill and Wright (1933) that bactericidal 
antibodies against an encapsulated strain of influenzae 
could not be demonstrated in blood samples from children 
between the ages of 2 months and 3 years, but were more common 
in children between 3 and 10 years, and constantly present in 
the blood of older children and adults. 
The capsular polysaccharide antigen of influenzae 
type b contains D-ribose phosphate, in the form of poly- 
ribophosphate (Zamenhof et al., 1953). Argaman et al., 1974 
found that the structure contained equimolar amounts of ribose, 
ribitol and phosphate (Crisel et al., 1975). This antigen is 
the principal virulence determinant of influenzae type b 
(Alexander, 1958), and there has been recent interest in its 
potential as a protective immunogen (Robbins et al., 
Smith et al., 1973). 
1973; 
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Glode et al. (1976) have shown that the risk of gram¬ 
negative bacterial meningitis is highest for neonates. The 
most frequent gram-negative species causing neonatal bacterial 
meningitis is Escherichia coli (Johnson and Alvin, 1971). 
Strains with the K1 capsular polysaccharide account for about 
80% of these cases of meningitis (Sarff et al., 1975). The 
pathogenic role of K1 is also demonstrated because it is the 
most common capsular type in neonatal septicemia without men¬ 
ingitis and in childhood pyelonephritis (McCracken and Sarff, 
1974). 
K1 strains are found frequently in high concentrations in 
stools of healthy individuals of all ages, including newborns 
(Sarff et al., 1975). Analysis of col i serotypes in 
cerebrospinal fluid (CSF) from newborns indicates that most 
strains can also be simultaneously detected in the infant and 
maternal stool. Maternal-infant transmission also occurs 
without development of disease (Sarff et al., 1975). 
An acidic amino polysaccharide termed colominic acid was 
secreted into the culture medium by the colocingenic strain of 
Escherichia col i K1, (Eh_ coli ; Barry, 1959). This poly¬ 
saccharide was composed of repeating units of N-acetylneura- 
minic acid. This was the first time that sialic acid had been 
found in other than mucopolysaccharides derived from mammalian 
sources. A survey was made to determine if these substances 
occurred in other E. coli strains and in different species of 
bacteria. Of 19 strains of E. coli examined only two gave a 
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positive test for sialic acid: E^_ col i K5 and E_^_ col i Kl. The 
K antigen that forms a capsule in these strains is colominic 
acid. 
Morphologically, the C_^_ neoformans cell is surrounded by 
a mucoid polysaccharide capsule of varying thickness that is 
composed of xylose, mannose and glucuronic acid (Cherniak et 
al., 1980). Schutzbach et al. (1972) made a study of lau- 
rentii that resembled the human pathogen neoformans. These 
investigators prepared a cell-free extract containing glycosyl 
transferases that catalyze the synthesis of a cell envelope 
glycoprotein. 
Raizada et al. (1974) studied the enzymatic transfer of 
galactosyl residues from UDP [1^C] galactose to the cell 
envelope glycoprotein. The labeled material was chromato¬ 
graphed on a column of Sepharose 4B and eluted as a single peak. 
The purified glycoprotein contained 70% carbohydrate and 30% 
protein. Mild acid hydrolysis of the glycoprotein revealed the 
monosaccharides mannose, galactose and xylose. Galactose was 
the only radioactive monosaccharide constituent. After treat¬ 
ment with NaOH-NaBH4 , the radioactive materials no longer bound 
DEAE-cellulose. Subsequent analysis by gel filtration on 
Sephadex G-25 showed a peak of approximately 2000 molecular 
weight, suggesting the liberation of a dodecasaccharide chain. 
These data suggested addition of multiple galactosyl residues 
to an endogenous glycoprotein acceptor. 
Raizada, et al. (1974) demonstrated transfer of mannosyl 
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and galactosyl residues from GDP-[14C]-mannose and UDP[3H] 
galactose to the same endogenous acceptor. The labeled ma¬ 
terials were placed on a Concanavalin A (Con A) Sepharose column 
and the bound material was eluted with alpha-methyl glucoside. 
After beta elimination with NaOH-NaBH4, only the -^C labeled 
sugar remained bound to Con A. The data were consistent with 
a glycoprotein structure in which the three types of oligo¬ 
saccharides are bound to a common polypeptide core through an 
O-glycosidic linkage to threonine and serine of the peptide 
moiety. 
Several investigators (Cherniak et al., 1980) made a study 
of the polysaccharide capsule of C. neoformans serotype A. The 
capsule consisted of glucuronoxylomannan (GXM), containing 
molar ratios of xylose:mannoseiglucuronic acid: 0-acetyl of 
2:5:1:2. The xylose and glucuronic acid occurred as single 
pyranosyl residues and were oxidized by periodate; the Smith- 
degraded product (Goldstein et al., 1975) was an insoluble 
mannan. Mannose was linked (1-3) with three out of five mannose 
residues (1-2)-substituted with one glucuronosyl and two sin¬ 
gle xylosyl end groups. A repeating octasaccharide was pro¬ 
posed as the structure. Glucuronic acid was ruled out as the 
site for O-acetylation based on the periodate sensitivity of 
the glucuronyl residues. The repeating octasaccharide is one 
of the several possible structural models compatible with the 
experimental data. Variation in the spacing of the xylosyl 
residues, so that glucuronic acid and xylose may be adjacent, 
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could account for some of the immunological properties of the 
antigens. 
Although a symmetrical repeating unit is the most 
straight-forward interpretation of the data, two polysaccha¬ 
ride components were demonstrated as immunoprecipitin arcs in 
immunodiffusion (ID) in this study and also by others (Bennett 
and Hasenclever , 1965). One of these antigenic factors was a 
minor component that had affinity for agarose-bound sero¬ 
type D-IgG. This is probably the common antigen for the species 
Filibasidiella neoformans which is composed of serotypes A and 
D of neoformans. The major component appearing in column 
effluent contained the partially purified serotype A specific 
factor. 
Antigenic Structure Related to Cell-Mediated Immunity 
Circumstantial evidence (Diamond, 1977) strongly suggests 
that human exposure to C_^ neoformans is common but that failure 
of immunity and extrapulmonary cryptococcosis is rare (Powell 
et al., 1972). Development of disseminated cryptococcosis in 
man correlates with abnormalities in cell- mediated immunity as 
determined by in vitro tests (Diamond and Bennett, 1973; 
Graybill, 1974; Schimpff, 1975). C^_ neoformans can be killed 
in vitro by phagocytic neutrophils (Diamond et al., 1972; 
Tacker et al., 1972), monocytes (Diamond et al., 1972; Diamond 
and Bennett, 1973) and macrophages (Mitchell and Friedman, 
1972; Sethi and Pelster, 1974), as well as by nonphagocytic 
mechanisms involving monocytes or macrophages (Kalina and 
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Aronson, 1974) or by leukocytes requiring specific anticrypto- 
coccal antibodies (Diamond and Allison, 1976). Stimulation and 
suppression of cell-mediated immunity in cryptococcosis were 
studied in guinea pigs because this species, like man, is 
resistant to corticosteroids. Guinea pigs may develop a 
relatively chronic form of experimental cryptococcosis, facil¬ 
itating studies of factors that shorten or prolong survival. 
Female guinea pigs survived longer than males; perhaps this 
reflected a greater capacity of monocytes of the females to kill 
cryptococci. It was noticed that a brief treatment with 
cortisone shortened the survival of females and resulted in 
depression of inflammatory responses long after cortisone was 
stopped. 
There has been a decline in the use of skin tests for 
delayed-type hypersensitivity (DTH) in the diagnosis of fungal 
infection because of the unpredictability of positive reac¬ 
tions, lack of specificity of the antigens used, and their 
interference with the results of other diagnostic tests such as 
complement fixation (Buechner et al., 1973). Nevertheless, an 
evaluation of the ability of fungal antigens to elicit cellular 
immune responses may still be of value in epidemiology, in an 
assessment of the immunological competence of the host, and in 
research to delineate the in vitro responses of various lympho¬ 
cyte populations. It is possible that with a more suitable 
antigen, skin testing could be of use either diagnostically or 
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prognostically, or at least would contribute to our under¬ 
standing of the role which cellular immune responses play in 
infection (Hay and Reiss, 1978). 
Polysaccharides such as the capsular polysaccharide of C. 
neoformans are poor skin test antigens because they evoke 
immediate hypersensitivity of the Arthus type that merges 
confusingly with true delayed reactions. Another reason for 
avoiding the presence of acidic polysaccharides is because they 
were shown in the instance of pneomococcal type III capsular 
polysaccharide to induce immunological tolerance by a "tread¬ 
mill" effect. Circulating polysaccharide neutralizes antibody 
as it is synthesized and also inhibits or decreases the number 
of antibody-producing cells determined as hemolytic immuno- 
plaques (Howard et al., 1970). Special steps are required to 
remove cryptococcal polysaccharide from antigens used in skin 
tests and blastogenesis assays or alternatively an acapsular 
mutant may be used for antigen production. 
Murphy and Cozad (1972) studied a cryptococcal culture 
filtrate antigen that elicited DTH reactions in guinea pigs and 
mice infected with neoformans (Murphy et al., 1973; Cauley 
and Murphy, 1979). The antigen was specific for C. neoformans 
and did not elicit DTH in guinea pigs sensitized with Histo- 
plasma capsulatum, Blastomyces dermatitidis, Sporothrix 
schenckii, Candida albicans or Cryptococcus albidus. Murphy 
and Pahlavan (1979) found that if the culture filtrate antigen 
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was subjected to ultrafiltration, the skin test active com¬ 
ponents were in the 50,000 or greater molecular weight range 
fraction. 
Hay and Reiss (1978) prepared a subcellular fraction of a 
small capsule form of C_^ neoformans that elicited DTH in 
sensitized mice and guinea pigs. Antigen-specific footpad 
swelling in mice and skin testing of guinea pigs were achieved. 
Two fractions, the postmitochondrial supernatant, and the 
culture filtrate, showed considerable activity in the footpad 
test, with 26 1 and 30 1 at 24 hr swelling, respectively, at 
6 weeks after infection. With the culture filtrate antigen 
there was interference from a strong antibody-mediated 4 hr 
skin reaction, due to the presence of capsular polysaccharide. 
The postmitochondrial supernatant produced strong DTH in gui¬ 
nea pigs at a dose of 69 g, and there was no crossreactivity 
at this dose in animals sensitized with dermatitidis, C. 
albicans or H^ capsulatum. 
Hay and Reiss (1978) infected mice with C_^ neoformans by 
three ways: intravenously (i.v.), subcutaneously with live 
yeast and i.v. with killed yeast. Migration inhibition was 
measured at 5 and 6 weeks after the initial infection. A higher 
level of migration inhibitory factor (MIF) production, indi¬ 
cating a strong cellular response, was obtained in the sub¬ 
cutaneously infected than in the intravenously infected group, 
which showed poor responses. This trend was confirmed by 
repeated tests in a group which had not been subjected to weekly 
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skin testing. Groups of four mice were used. Again, mice 
infected subcutaneously, developed larger responses than those 
infected intravenously with either live or killed C^_ neo- 
formans. In addition, it was found that viable organisms could 
not be identified in smears or cultures in the subcutaneous 
group after the first week. This contrasted with mice injected 
intravenously who were infected in at least two sites, usually 
brain and lung, for the duration of the experiment. This result 
was taken as evidence for suppression of cell mediated immunity 
in disseminated cryptococcosis. 
Fromtling et al. (1979) studied cell-mediated immune re¬ 
sponses in mice immunized with two avirulent forms of C. 
neoformans: an acapsular mutant and a thinly encapsulated 
pseudohyphal variant. The lymphocyte transformation assay was 
used to evaluate the cellular response of spleen cells from 
sensitized mice after in vitro incubation with merthiolate- 
killed whole cells of C^_ neoformans used as the antigen. Spleen 
cells from mice inoculated intraperitoneally for 6 consecutive 
weeks with 10^ viable NU-2-P cells gave a maximum lymphocyte 
transformation response in a 10:1 yeast cell to splenocyte 
ratio. 
Clinical Significance of Cryptococcal Antigens 
The latex agglutination test (L.A. , Bloomfield et al., 
1963) detects the soluble capsular polysaccharide antigen of 
the yeast in cerebrospinal fluid (CSF) of cryptococcosis pa¬ 
tients. The latex particles are coated with rabbit antibody 
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produced by immunization with formalin-killed whole cells and 
can detect polysaccharide in the low ng/ml range. 
The indirect fluorescent antibody test, I FA (Vogel et al., 
1966) is used to detect circulating antibodies against the 
capsule of the yeast. This test is performed on a microscope 
slide by allowing a serum sample to react with formaldehyde- 
killed neoformans cells. The indicator antibody is fluores- 
cein-labeled-antihuman IgG. 
Pathogenic yeast and many of the bacteria that can cause 
meningitis in humans contain a capsule made of acidic poly¬ 
saccharide. Pathogenic yeast and bacteria with small capsules 
can be more easily phagocytized by monocytes whereas large 
capsule organisms are much more difficult in this respect 
(Mitchell and Friedman, 1971). 
The extent of exposure in the general population to C. 
neoformans is unknown because of inadequate epidemiological 
surveys and the lack of an adequate skin test reagent. A better 
skin test reagent should facilitate surveys in the normal 
individuals and those in high risk groups. This study was 
designed to develop antigens suitable as skin test reagents and 
for the lymphycote blastogenesis assay. The culture for 
antigen production in the present research was an acapsular 
mutant of neoformans and was selected in order to minimize 
the presence of the capsular polysaccharide which is a stimu¬ 
lant of immediate hypersensitivity. A cell free extract was 
prepared and differential centrifugation produced a 105,000 x g 
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soluble supernatant and a microsomal fraction. The use of such 
purified fractions from an acapsular mutant is without prece¬ 
dent and increased the chances of obtaining a potent and 
specific antigen for assessing cutaneous hypersensitivity and 
its in vitro correlate in crypto-coccosis. Blastogenesis of 
lymphocytes populations from infected guinea pigs was deter- 
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mined by measuring the incorporation H thymidine into lympho¬ 
cyte DNA. 
CHAPTER III 
MATERIALS AND METHODS 
C. neoformans 602 was obtained from Dr. Thomas R. Kozel, 
University of Nevada, Reno, Nev. It was isolated in 1957 from 
the spinal fluid of a patient with cryptococcal meningitis. 
Although originally of serotype D, after repeated transfers it 
lost the ability to produce a capsule and was untypable by the 
method of Wilson et al., 1968, as serotype A, B, C or D. Since 
then it has remained a stable acapsular mutant. It is main¬ 
tained in the Mycology Division as No. B-2556 (Center for 
Disease Control [CDC], Atlanta, Ga.). C. neoformans 371A was 
obtained from the National Institutes of Health (N.I.H.), 
Bethesda, Md. It is maintained in the Mycology Division as C. 
neoformans B-2550. This culture was isolated from soil and has 
a large capsule. CDC originally obtained C^_ neoformans B-551 
from W. C. Eveland, University of Michigan, Ann Arbor, Mich, in 
1963. This strain was originally designated ODH 127DV. C. 
neoformans B-551 is a small capsule form of serotype A obtained 
by exposing the wild type to the disinfectant "Wescodyne." 
Cultures are kept overlaid with sterile mineral oil on Potato 
Dextrose Agar (PDA) slants and Sabouraud agar slants with 
chloramphenicol (Sab + C) as a bacteriostat. Seeding and 




Several types of media were tested to determine which 
would give the highest Cj_ neoformans yield at 24, 36 and 48 hr. 
A liter of each medium was prepared and 250 ml portions were 
dispensed into 1 liter Erlenmeyer flasks with cotton plugs 
wrapped in gauze used as stoppers. Media were autoclaved for 
20 min at 15 lb/in^ at 123 C. The media had the following 
composition in grams per liter of deionized water: (1) High 
phosphate medium: glucose, 15; urea, 1.29; KH2PO4, 5.44; MgSC>4, 
0.3; thiamine, 0.02; yeast extract, 0.2 and trace elements 
(Mn++, Fe++, Zn++ = 10_3M, Cu+++ = 10"6M and Ca++ = 10_4M). The 
pH after autoclaving was 6.4. (2) Salvin's modified medium 
(1947): casein hydrolyzate (Bacto-casitone, Difco Laborato¬ 
ries, Detroit, Mich.), 10; glucose, 10; yeast extract (Difco), 
3; L-cysteine hydrochloride «H2Û, 0.04; KH2PO4, 1.77; K2HPO4, 
1.22, and MgSC>4.7H20, 0.01. The pH of the medium after 
autoclaving was 6.3. (3) Mager's medium (Mager, 1947) - 
glucose, 20; urea, 1; MgSC>4*7H20, 0.5 and thiamine»HC1, 0.02. 
The pH of the medium after autoclaving was 6.9. 
A 48 hr culture of C_^ neoformans was grown at 37 C on PDA 
slants. Three ml of each medium were added to each slant. A 
sterilized loop was used to agitate the yeast cells from the PDA 
slant surface. The cell suspension was then used to seed 250 
ml of broth in a 1-liter flask. All used pipets and glassware 
were decontaminated with 2% Amphyl (soap, anhydrous 44.0%; 
0-phenylphenol 15.0%; p-tert-amylphenol 6.3%; alcohol 4.7% 
(National Laboratories, Link and Fink Industrial Product Divi¬ 
sion, Toledo, Ohio), the general purpose disinfectant. Flasks 
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were placed in a Psycrotherm incubator-gyratory shaker model 
No. G526 (New Brunswick Scientific Co., New Brunswick, N.J.) 
and incubated at 35 C at 150 rpm for 24 hr, then 10 ml aliquots 
of seed cultures were transferred to flasks for sampling at 24, 
36 and 48 hr. As the growth times elapsed the culture flasks 
were merthiolated (sodium ethylthiomercurisalicylate; Aldrich 
Chemical Co.) to give a final concentration of 0.02%, wt/vol. 
The merthiolated cells were replaced on the gyratory shaker for 
4 hr to insure uptake of the drug and then stored in the cold 
overnight. Sterility was checked on Sab + C slants after in¬ 
cubation at 37 C for 72 hr. 
Batch Cultures for Antigen Production 
Batch cultures for antigen production were grown in 15 
one-liter flasks, each containing 250 ml of Salvin's modified 
medium. Each flask was seeded with 10 ml of a 24 hr starter 
culture and incubated at 30 C at 150 rpm for 36 hr. Then 
merthiolate was added to give a final concentration of 0.02% 
wt./vol. 
Preparation and characterization of antigens (Fig. 1-3). 
Merthiolate-killed yeast cells were harvested by centri¬ 
fugation (9200 x g, 20 min) , washed twice in 0.85 M NaCl and in 
deionized water. The cells were washed in tris (hydroxymethyl) 
aminomethane hydrochloride buffer (tris), 0.1 M, pH 7.5, con¬ 
taining 1 mM glutathione, 1 mM disodium ethylenediaminetetra- 
acetate (EDTA) and resuspended in that buffer to give a packed 
cell to buffer ratio of 1:1.5, vol/vol. Aliquots of the cell 
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Cryptococcus neoformans 602 
Salvin's modified medium 
I 
Seed flask—24 hrs, 35°C, 150 rpm 
I 
24 hr culture 
10 ml/300 ml of medium x 15 flask 
X incubate 36 h, 30°C, 150 rpm 
add 2% merthiolate, 3 ml/flask = 0.02% 
f  
Sterility (3 tubes) 
Check 
24 and 48 hr at ▼ 
incubated @ 37°C Harvest 9200xg(7.500 rpm) for 20 min. 
( i y res: 
Sup't: Wash 2x in 0.85% 9200xg, 20 min 
discard  J 
y res. 
Sup't Deionized H2O—9200xg, 20 min 
disc. I 
y res: 
Sup't: Tris HCI+EDTA+glutathione, 
disc. CRU 5000 centfg. 
t res: 
Sup't Adjust packed cells: buffer 
disc. = 1:1.5 vol/vol. 
▼ 
32.5 ml suspension + 27 ml glass beads 
per 60 ml screwcap serum bottle 
1 
▼ 
Let stand overnight in an ice bath 
Fig. 1. Flow diagram showing preparation of microsomal frac¬ 
tions from C^_ neoformans. (Continued on pages 26 and 
27) . 
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yeast cell suspension 
+ glass beads, 60 ml screwcap bottle 
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Braun cell homogenizer 
I 
2 min treatment 
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1 min treatment 
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aspirate homogenate w/o beads 
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cntrfg., 5090xg, 20 min 
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Supt: 
reserve in 50ml 
Oak Ridge tubes 
in ice bath 
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crude cell walls, 
freeze 
Res: intact cells + walls 
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packed cells: buffer = 1:1, vol/vol 
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in closed circulating system 
in — 5°C bath 
cntrfg, 9200xg, 20 min 
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reserve 














Pellet - resuspend in buffer 
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Pool buffer —EDTA, glutathione 
I 
Resuspend with Tris R Tissue Grinder 
t 
Microsomal fractions 
dispense 0.5 ml aliquats in 
1 dram vials and store at — 40°C 
Fig. 3. Antigen preparation scheme, continued. 
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suspension, 32.5 ml, plus 42.5 g (or 27 ml) of 0.45-0.5 mm 
diameter glass beads (Glasperlen, VWR Scientific Inc., At¬ 
lanta, Ga.) were combined in 60 ml screw cap serum bottles and 
disrupted in a Braun cell homogenizer for 3 min. During the 
disruption the bottles were cooled by a continuous stream of 
liquid CO2. Intervals of 1, 2, 3, 4 and 5 min were tested to 
see which would give the maximal cell breakage (Fig. 4 and 5). 
After allowing the beads to settle, the homogenate was as¬ 
pirated, pooled (202 ml) , and centrifuged (5090 x g, 20 min) to 
sediment intact cells and cell walls. All subsequent steps were 
carried out at 4 C. The supernatant was centrifuged at 
12.000 x g for 15 min; the pellet was discarded and the 
supernatant was ultracentrifuged (Model L-2 Beckman Instru¬ 
ments, Fullerton, Calif.) in a fixed angle rotor, SW 41, at 
105.000 x g (37,000 rpm) for 1 hr. The supernatant was a clear 
liquid and the middle layer or microsomal fraction was light 
brown. The lower layer was a clear gel, possibly glycogen, and 
was stored at -40 C. 
The 105,000 x g supernatant, (105K), was dialyzed versus 
potassium phosphate buffer (0.025 M, pH 7.4 containing 0.07 M 
NaCl), then lyophilized and stored at -40 C. The pellets 
obtained at 105,000 x g were pooled, resuspended in tris buffer 
and recentrifuged. The final 105,000 x g pellets, designated 
the microsomal fraction (gs) were resuspended in tris buffer 
without EDTA and glutathione with a tissue homogenizer (Tri-R 
Instruments, Rockville Centre, N.Y.) and stored in 0.5 ml 
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Fig. 4. Mechanical disruption of neoformans whole killed 
yeast cells with glass beads in a Braun cell homogen- 
izer. A, zero time; B, 1 min treatment, and C, 2 min 
treatment. C-arrows point to whole cell and CW- 
arrows point to cell wall. 
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Mechanical disruption of C. neoformans whole killed 
yeast cells with glass bead in a Braun cell homo- 
genizer. A, 3 min treatment; B, 4 min treatment; and 
C, 5 min treatment. CW-arrows point to cell walls. 
Fig. 5. 
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aliquots at -40 C. A postmitochondrial supernatant (PMS) was 
prepared from C_^ neoformans B-551 by the method of Hay and Reiss 
(1978) . Capsular polysaccharide was prepared from neo¬ 
formans 371 serotype A by the method of Cherniak et al. (1980) . 
The 5090 x g sediment consisting of glass beads, whole 
cells and cell walls, was resuspended in tris-EDTA-glutathione 
buffer and the cell suspension was aspirated to free it from 
glass beads. This step was repeated until no glass beads were 
carried over with the cells. This suspension was sonified for 
1 hr at 70 watts in a continuous flow closed circulating system 
cooled in a -5 C ethylene glycol-water, 1:1 vol/vol bath (Fig. 
6). Following Bonification the suspension was sedimented at 
5090 x g for 20 min and the supernatant was treated in the same 
way as the initial Braun homogenizer-treated fraction. 
Protein Determination 
The protein content of each antigen was determined using 
Folin-phenol (Lowry et al., 1951). A sufficient amount of the 
Lowry reagent (A) was prepared in the following manner: 8 ml 
of deionized water was added to 18 x 150 mm test tube and then 
1 ml of 5% CUSO4 was added (swirl) . One ml of 20% sodium 
tartrate was then added to the solution, giving a total volume 
of 10 ml of reagent A. Second, 176 ml of deionized water and 
20 ml of 20% NaC03 in 1 N NaOH were combined in a 250 ml Erlenmyer 
flask (reagent B) and the 4 ml of reagent A was added to make 
reagent C. Duplicate standard tubes were set up containing 
10/Zg to 200yug of bovine serum albumin fraction V, 1 mg per ml 
32 
f 
Fig. 6. Diagram of the closed loop cell sonification system. 
A cell suspension of neoformans was introduced at 
the reservoir (d) . The cells were pumped (c) to the 
sonification chamber (a) and then the disrupted 
cells were continuously recycled. Arrows show the 
direction of flow. A refrigerated bath (e) was 
maintained at a constant temperature of -10 C by a 
circulating cooler (f). 
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of 0.85% saline stock solution, (Lot No. 305, Pentex, Miles 
Laboratories, Elkhart, Ind.). Serial two-fold dilutions of 
each antigen were arranged in the same manner as the standard 
tubes. Five ml of reagent C was added to each tube, then 
vortexed and left standing for 10 min. Next 0.5 ml of a 1:1 
aqueous dilution of Folin-phenol reagent (Fisher Scientific 
Co., Pittsburgh, Pa.) was added quickly and immediately vor¬ 
texed. Tubes were left standing for 30 min, and then the 
optical density was determined using the Klett Summerson 
Photoelectric Colorimeter (Klett Manufactory Co., Inc., Model 
No. 800-3) with a red No. 66 filter. Klett units were converted 
to micrograms of protein with respect to the bovine serum 
albumin standard curve. 
Column Chromatography 
An ion exchange column containing diethylaminoethyl 
(DEAE) Sephadex A-50 was prepared for the PMS. Approximately 
20 g of DEAE Sephadex A-50 (Pharmacia Fine Chemicals, Piscata- 
way, N.J.) was prepared in 0.025 M cold Tris-HCl buffer, 
pH 7.31, and the pH was adjusted with 1 N NaOH. A 2 x 24.5 cm 
column was poured in the cold, 4 C,and equilibrated with buffer 
until the effluent pH was 7.3. A peristaltic pump (Sage 
Instruments, Model 375A) was connected to the column to give a 
controlled flow rate of 50 ml/hr. The conductivity of the PMS 
sample was determined before placing it on the DEAE column. The 
PMS had a conductance of 1600.6 reciprocal ohms. A dis¬ 
continuous gradient of NaCl in phosphate buffer was used to 
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elute the bound solutes with these concentrations (M): 0.05, 
0.1, 0.2, 0.3 and 0.5 (200 ml of each solution). Two ml 
fractions (1-94 tubes) were collected and monitored for protein 
with an ultraviolet flow analyzer (Uvicord II, LBK-Produkter, 
Bromma, Sweden) at 280 nm connected to a strip chart recorder. 
Fractions showing peaks of absorbance were pooled and the 
protein content was determined (Fig. 7). 
The phenol-sulfuric acid test was used for the detection 
of total carbohydrate (Hodge and Hofreiter, 1962). The first 
25 fractions that eluted from the Sephadex column were pooled 
and concentrated to 288 ml by filtration under N2 pressure in 
an Amicon ultrafiltration cell over a PM10 membrane (Diaflo, 
Amicon Corp. , Lexington, Mass.) versus phosphate buffer 
(Fig. 8). Eighty-eight ml of this effluent were placed on a 
column of a concanavalin A-agarose (Con A-Sepharose; Pharmacia 
Fine Chemicals, Piscataway, N.J.). The effluent was dia- 
filtered versus phosphate buffer solution (PBS), lyophilized, 
and the protein determined. An additional 100 ml were aspirated 
from the 288 ml effluent and centrifuged at 20,000 x g for 
30 min. The supernatant was diafiltered versus PBS and then 
lyophilized. The residue was divided in half and one portion 
was treated with 0.5% sodium deoxycholate, then centrifuged at 
20,000 x g for 30 min. The second half of the residue was 
treated with 0.5% Triton X100 (Eastman Kodak Co., Rochester, 
New York). The Triton extract was centrifuged at 20,000 x g for 
30 min, the supernatant was aspirated, then diafiltered. The 
























Fig. 7. Elution profile of the postmitochondrial supernatant 
from C^_ neoformans B-551 using a sodium chloride 
gradient fractionation on DEAE-cellulose. Concen¬ 
trations of sodium chloride in the phosphate buffer 
are shown. A UV flow analyzer operated at 280 nm was 
used to detect proteins in the column eluate. Frac¬ 
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The sample was prepared by the pseudoreplica technique 
(Martin et al. , 1975). Approximately 0.5 ml of us was suspended 
in 3 ml of 2.0% agarose. After the droplet diffused and 
evaporated the block was flooded with 0.5% Formvar (Ernest F. 
Fullam Inc., Schenectady, N.Y.) in ethylene dichloride. The 
Formvar membrane containing the sample was floated onto a 2.0% 
potassium phosphotungstate solution, pH 6.0. A 400-mesh copper 
grid was placed over the membrane and then dried. The sample 
was examined with a Philips 201 microscope (Philips Co., Mount 
Vernon, N.Y.). Internal calibration was determined with cata¬ 
lase crystals, Luftig (1967). 
Polyacrylamide Gel Electrophoresis 
The PMS, JAs and 105K antigens were analyzed using a 
discontinuous gel with sodium dodecyl sulfate (SDS) in tris 
buffer and contained a stacking gel above the resolving gel 
(Obijeski et al., 1974). The 10 cm resolving gel of 10% 
(wt/vol) acrylamide, 0.27% N, N'-methylenebisacrylamide (bis), 
in 0.375 M-tris buffer, pH 8.9, containing 0.1% SDS was poly¬ 
merized in the presence of 0.025% N,N,N', N'-tetramethyl- 
ethylenediamine (TEMED) and 0.08% ammonium persulfate. The 
1 cm stacking gel contained 3.1% wt/vol acrylamide, 0.07% bis, 
0.1% SDS, 0.03% TEMED and 0.08% ammonium persulfate dissolved 
in 0.125 M-tris buffer, pH 6.8. The electrode buffer (pH 8.3) 
contained 0.05 M tris, 0.384 M glycine and 0.1% SDS. Gels were 
electrophoresed at 2.5 mA/gel for 4 hr. The molecular weights 
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of cryptococcal proteins were estimated with respect to ve¬ 
sicular stomatitis virus (VSV, Indiana) protein standards 
(Obijeski et al. , 1974) having the following molecular weights: 
M-27,000, N-46,000, NS-54,000, G-63,000 and L-149,000 da. 
Immunization of Guinea Pigs with Adjuvant 
Guinea pigs were immunized with C^_ neoformans 602 mer- 
thiolate killed whole cells in complete Freund adjuvant (Her¬ 
bert, 1967) . The oil phase was made by mixing light mineral oil, 
Drakeol 6VR, and the emulsifier, mannide monooleate (Arla- 
cel A) in the ratio of 65:35 vol/vol. This solution was 
sterilized in an autoclave for 40 min. Heat-killed and dried 
mycobacteria, 30 mg, (Mycobacterium tuberculosis var. hominis 
strain DT612) were placed in a small mortar and 6 ml of the 
oil-Arlacel was added in dropwise, then macerated with a 
pestle. Mycobacteria were a gift from Dr. Merle Selin (CDC, 
Atlanta, Ga.). Precautions were taken during the preparation 
of the adjuvant to wear gloves and goggles. The aqueous phase 
of the adjuvant consisted of 2 mg/ml suspension of lyophilized, 
merthiolate killed C_^ neoformans 602. A water-in-oil emulsion 
was prepared by placing the oil phase in a beaker (5.0 ml) , then 
the aqueous phase was added dropwise and emulsified with a 
syringe and a 19 gauge needle. The final mycobacterial concen¬ 
tration was 2.5 mg/ml. The nuchal area of 4 guinea pigs were 
shaved and 1 ml of antigen in adjuvant was distributed in five 
sites. 
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Guinea Pig Skin Tests 
The yeast was grown on PDA for 48 hr at 37 C. Serial 
two-fold dilutions were made in 3% acetic acid containing 0.01% 
of crystal violet (Turk's stain). The stain killed the cells 
and increased their visibility for counting purposes. Three ml 
of dense cell suspension was placed in a sterile 50 ml screw cap 
Erlenmyer flask. One ml of cell suspension was aspirated and 
serially diluted in Turk's stain. Diluted cells were counted 
in a hemocytometer chamber (American Optical, Buffalo, N.Y.) 
using the 40X objective of a binocular microscope (Leitz, 
Wetzlar, Germany). The required volume of undiluted cells was 
calculated and diluted in a 0.85% sterile saline to give a final 
concentration of 1 x 107 cells/ml. After shaving the abdomen, 
the guinea pigs were anesthetized with ether in a jar and 
injected i.p. with live cells of neoformans B-551. Another 
group of 4 animals was injected with 1 x 107 cells of acapsular 
C. neoformans 602. 
Large (500-600g) guinea pigs (CDC) were separated into 
three groups of four animals. The first or control group was 
not infected with live cells but skin tested weekly for four 
weeks with PMS, 105K supernatant and jus fraction. Each antigen 
was injected intradermally in the flanks and standardized on 
the basis of protein content to give 10, 50 and 100,11g doses. 
The second group was injected intraperitoneally (i.p.) with 1 
x 107 live neoformans B-551, a small capsule culture of 
Serotype A. Yeast cells used for injection were grown on 
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Sabouraud agar slants for 48 hr. Animals in the third group 
received 1 x 10^ cells of the acapsular C. neoformans 602, i.p. 
After two weeks had elapsed, each group then was skin tested 
weekly for four weeks with the antigens and doses given above. 
Skin test activity was determined at 4, 24 and 48 hr intervals, 
and the results were expressed as mean squared radii of in¬ 
duration + standard deviation (r2). The specificity of the 
antigens were tested further on guinea pigs sensitized with 
Histoplasma capsulatum A811 (CDC), or Candida albicans 3181A 
(CDC) . Groups of 4 animals were injected i.p. with 1 x 10^ (48 
hr culture) C\_ albicans. After three weeks elapsed, these 
animals were skin tested. The total antigenic load in these 
primed animals is shown in Table 1. 
Lymphocyte Transformation Assay (LTA) 
In the first experiment, after completion of the last skin 
test the animals were rested for 7 days and then injected with 
lOO^Ug of ^s in each hind footpad to stimulate the popliteal and 
inguinal nodes. On the following week, the animals' footpad 
injections were repeated and they were also injected i.p. with 
20 ml sterile mineral oil (Drakeol 6VR, Penreco Co., Butler, 
Pa.). After 72 hr, the animals were anesthetized with ether, 
exsanguinated, and the peritoneal exudate cells (PEC) of each 
animal was harvested by washing the peritoneal cavity with 
Hanks' Balanced Salt Solution (HBSS). 
The spleens, superficial and deep inguinal and popliteal 
nodes were removed from each animal and kept separate. The PEC 
Table 1. 
41 
A schedule for injection of live yeast and subcellular antigens of C. neoformansa in five 
guinea pigs 
Time Elapsed, days 




Live yeast 1 x 107 
cells 
i-p.b y 1 x 107 
105KC 100 ug 
protein 
i.d.d 
/ y y y y y 600 
/iSc 100 ug 
protein 






y y y y y y 
600 
PSf 7.5 mg i.p. J 7.5 mg 
minerals 
oil 
20 ml i.p. y 20 ml 
aC neoformans B-551 or 602 
^intraperitoneally 
C1()5K x g supernatant 
^interdcrmal in the flasks 
emicrosomal fraction 
1 capsular polysaccharide was injected ip in one group 2 weeks before infection and skintesting 
^mineral oil was injected in all animals 72 hr before sacrifice 
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were centrifuged (1250 rpm, 12.5 min.), washed once with 
RPMI 1640 medium (GIBCO, Grand Island, N.Y.) and resuspended to 
give a cell density of 2.5 x 10^ cell/ml. The spleens were 
transferred to 7.5 cm diameter stainless steel sieves, 60 mesh 
(Newark Wire Cloth Company, Newark, N.J.) having an opening 
size of 250 J$n. Spleens were cut into fragments and gently 
pushed through the screen with a rubber tip syringe plunger. 
The spleen cell suspension was allowed to stand for 10 min so 
that large aggregates could sediment. The upper phase was 
aspirated and centrifuged at 1250 rpm for 12.5 min. The cell 
pellet was washed once in RPMI 1640 medium and resuspended to 
give a densisty of 2.5 x 10^/ml. The lymph nodes from each 
animal were prepared by passage through stainless steel sieves 
as described above, washed once in RPMI 1640 medium and adjusted 
to give a density of 2.5 x lO^/ml. in later experiments, the 
priming schedule was simplified and shortened. 
The LTA was performed in 96 well microtiter plates (Linbro 
IS-FB-96). The RPMI 1640 medium with the following additions, 
final concentration: L-glutamine, 300 mg/L; 2-mercaptoeth- 
anol, 5 x 10”3 M; penicillin, 200 /4g/ml; streptomycin, 
10.0/<g/ml and amphotericin B, 1/tg/ml. Some cultures received 
fetal calf serum, 10%, (Lot number 29101145, Flow Labor ator ies, 
Rockville, Md.). Each well of the culture received 0.2 ml of 
cell suspension, 25/41 of FCS or medium, and 25/|l of mitogen, 
antigen, or medium to yield a final volume of 0.25 ml. Cultures 
were set up in triplicate. The 105K fraction was filter 
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sterilized (0.45 porosity, Millex-25, (Millipore Corp. , 
Bedford, Mass.) and used at the following final concentrations: 
0.01, 0.1, 1.0 and lO^i/g of protein per ml. Because of its 
particulate state, the antigen was used directly without 
sterilization. 
The cultures were incubated at 37 C in a 5% CO2 atmosphere. 
Cultures were maintained for 4 or 6 days and pulsed 18 hr prior 
to harvest with 0.5 Ci of methyl-^H-thymidine (New England 
Nuclear, Boston, Mass.) in 50 1 of RPMI 1640 medium. The 
cultures were harvested on glass fiber filters, with the aid of 
a multiple automated sample harvester (Titerek Cell Harvester, 
Flow Laboratories, Rockville, Md.), using distilled water to 
lyse and wash the cells. Discs were transferred into 20 ml 
vials, and 2 ml of scintillation fluid containing 2,5- di- 
phenyloxazole (PPO), 0.5%, and 1,4 bis-2-(5-phenyloxazolyl)- 
benzene (POPOP), 0.3%, wt/vol in toluene were added. The 
triplicate samples were counted in a Beckman 6000 beta scin¬ 
tillation counter, and the results expressed as counts per min 
± standard deviation. 
Recovery of C. Neoformans from Infected Animals 
Portions of the spleen, PEC, lung, brain and peripheral 
blood were reserved. Brain, spleen and lung samples were placed 
into a Potter Elvehjem Tissue Grinder with a teflon pestle 
(Fisher Scientific Co., Atlanta, Ga.) and hand blended to a 
smooth paste. Three-tenths of an ml was applied to Sab + C agar 
plates, and sterile cotton tip applicator sticks were used to 
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distribute the tissue homogenate evenly. These petri dishes 
were incubated in a biological safety cabinet at room tempera¬ 
ture and observed for growth. 
CHAPTER IV 
RESULTS 
Media Used to Determine the Cell Yield 
of C. Neoformans 602 
Three media were tested at 35 C to see which would give the 
highest cell yield of C_^ neoformans 602 determined by centri¬ 
fuging the culture at 5090 x g and measuring the packed cell 
volume. Mager's and high phosphate media both gave 1 ml of 
packed cells per 50 ml at 24 hr and no further increase in yield 
at 36 and 48 hr. Salvin's medium gave 2.5 ml of packed yeast 
at 24 hr , 3.5 ml at 36 hr and 5.0 ml after 48 hr. Salvin's medium 
supported growth better than the other two media and was 
selected for antigen production. 
Acapsular C^ neoformans 602 were disrupted in a Braun 
homogenizer to determine the effect of time of homogenization 
on the extent of yeast cell breakage estimated by phase contrast 
microscopy. After 2 min, less than half of the cells were 
broken but more than 90% of the cells were broken after 3 min 
(Fig. 4-5). Three min was selected for use in the antigen 
production scheme. 
Column Chromatography 
The PMS antigen (341 ml) containing 7.35% protein was 
placed on a column of DEAE Sephadex (A-50) and the resulting 
peaks were pooled. Of the first 25 fractions that were eluted 
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a portion was chromatographed on Con A-Sepharose. Another 
portion that became insoluble was extracted with sodium deoxy- 
cholate (DOC) or with Triton. For details see "Materials and 
Methods." These 70 fractions were capable of eliciting posi¬ 
tive skin tests in guinea pigs sensitized with merthiolate- 
killed C_^ neoformans in complete Freund adjuvant, but also in 
normal animals (Table 2). This method of antigen preparation 
was abandoned because the factors responsible for nonspecific 
cutaneous activity could not be removed. 
Antigen Characterization 
When the homogenate of C^ neoformans 602 was centrifuged 
at 105,000 x g for 1 hr, the resulting microsomal fraction was 
recovered and had a protein content of 7.17 mg per ml. The 
protein content of the lyophilized 105,000 x g supernatant 
(105K) fraction was 10.2%. SDS-polyacrylamide gel electro¬ 
phoresis was carried out on the jus and 105K fractions (Fig. 9). 
To observe the proteins distinctly, large quantities of the 
fractions were necessary, 700 g of 105K protein and 860 g of 
us protein. In comparison with a VSV molecular weight standard, 
two major proteins were observed in the >ts fraction with 
molecular weights of 50,000 and 65,000 da. Several proteins 
were present in the 105K fraction with molecular weights 
estimated at 41,000, 45,000, 51,000, 55,000, 60,000, 85,000 and 
92,000 da (Fig. 10). Negative contrast electron microscopy 
(Fig. 11) showed that the/ws fraction contained heterogeneous 
electron dense and electronlucent membraneous materials. Ri¬ 
bosomes were also observed. 
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Table 2. Cutaneous reactivity in guinea pigs elicited by the Postmitochondrial Supernatant of Cryptococcus 







Cutaneous reactivity, Mean + S. E. C-C* 
Fractions 
4 hr 24 hr 48 hr 
Postmitochondrial 
Supernatant 622 52.2 312200. 79 ± 9 138 ± 12 68 ±8 
DEAE Sephadex 
1-25 (a) 
Con A 75 1.5 1150. 56 53 ±7 38 ±6 
Diafiltered 159 0.87 1383. 64 ± 8 92 ± 10 42 ± 6 
Deoxycholate 226 0.82 1853. 27 ± 5 37 ± 6 37 ±6 
Triton 
xlOO sol. 80 1.10 880 37 ± 6 62 ±8 21 ±5 
DEAE Sephadex 
Fractions 
56-57 72.2 0.80 576 86 ±9 80 ±9 24 ±5 
63-65 72 0.80 576 74 + 9 52 ±7 11 ±3 
66-67 48 0.60 288 103 ± 10 60 ± 8 23 ±5 
68-70 59 0.12 70 53 ±7 42 ± 6 32 ±6 
a See fig. 8 for flowdiagram, fig. 7 for elution profile 
b Protein determined by method of Lowry et al 
c Mean squared radius of induration ± standard error, 3 animal/group, 
d The antigenic doses were standardized at 100 ug of protein/site. 
48 
A B 
SDS-PAGE of us (A) and 105K (B) antigens. Markers 
indicate VSV protein standard : M, 27,000; N, 46,000; 
NS, 54,000; G, 63,000; L, 149,000 da. 
Fig. 9. 
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Relative Migration (mm) 
Distance 
Molecular weight estimation of cryptococcal proteins 
separated by SDS-PAGE with respect to VSV protein 
standards. Circles - VSV, rectangles - 105K, and 
triangles - ujs antigen. 
Fig. 10. 
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Fig. 11. Negative contrast electron microscopy of the £S 
antigen showing heterogeneous electron dense and 
translucent membraneous materials. R-arrows point 
to ribosome-like components. M-arrows point to 
pieces of cytoplasmic membrane. 
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Skin-tests 
The first intradermal (i.d.) injection of PMS,/is and 105K 
antigen into normal guinea pigs resulted in negative responses 
at doses up to 100/4 g of protein over the 48 hr period of 
observation (Table 3). Repeated weekly injections of these 
antigens resulted in a rapid buildup of reactivity. At the 50/<g 
dose, the 24 hr peak reaction of 39.9 mm2 was evoked by the 105K 
antigen after the second skin test. Cutaneous activity in 
noninfected animals toward the PMS and £s antigen also showed 
brisk responses after the second skin test. There was less 
activity on subsequent skin testing, except for the final test, 
when responses increased again. 
Guinea pigs injected with live neoformans B551 were 
skin tested after 2 weeks (Table 4) . For PMS antigen the 24 hr 
responses at the 50/Ug dose showed a maximum at the third week 
of 28 mm2 and then declined to a lower plateau for the remainder 
of the skin test period. The 24 hr peak response to the 105K 
antigen at the 50>*g dose was higher than other antigens tested. 
The maximum value of 32.1 mm2 occurred at 3 weeks postinfection 
(p.i.) , declined at the fourth week and then showed a slight 
increase. The/»s fraction elicited a moderately lower reaction 
on a weight basis than the other antigens tested; at the 50/4 g 
dose level, the 24 hr reactions were maximal at 3 weeks p.i., 
declined at the fourth week, then reached a higher plateau value 
in the next 2 weeks before declining slightly on the final week 
of skin testing. The 105K was the strongest of all antigens 
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Table 3. Cutaneous reactivity in normal guinea pigs tested with subcellular fractions of Cryptococcus 
neoformans 602 and B55I 





Hr 0 Wk. 1 Wk. 2 Wks. 3 Wks. 4 Wks. 
I2 ±s.d. 72 ±s.d. 72 ±s.d. 72 ±s.d. 72 ±s.d. 
B-S51 
13,000 x g 
PMS 10 4 0 2.0 0.4 8.5 4.8 1.3 0.6 23.9 19.0 
24 0 3.8 2.6 2.8 2.1 1.3 0.6 19.5 13.0 
48 0 1.7 2.0 0 0 2.4 3.5 
50 4 0 3.0 2.7 11.0 9.4 2.9 1.0 33.7 24.0 
24 0 21.8 15.0 7.7 4.5 5.2 4.0 17.8 5.7 
48 0 8.7 7.5 0.3 0.5 0 1.6 1.9 
100 4 0 8.9 6.6 10.4 14.0 3.6 1.2 35.3 25.0 
24 0 16.5 7.5 8.1 7.4 16.8 5.4 24.3 24.0 
48 0 13.4 15.0 1.0 1.4 2.6 2.8 3.4 3.1 
105,000 x g 
supernatant 10 4 0 4.0 3.1 13.7 11.0 4.2 3.3 31.0 21.0 
24 1.9 1.2 1.5 1.5 6.8 4.9 13.5 1 1.0 9.8 6.2 
48 0 0.3 0.6 0 0 1.0 1.1 
50 4 0 14.1 1.9 1 1.9 5.5 14.4 1 1.0 31.9 12.0 
24 1.8 3.0 39.9 15 17.4 13.0 9.0 7.2 12.0 6.5 
48 0.6 1.1 10.6 8.5 2.8 2.1 7.5 10.0 12.9 20.0 
100 4 0 16.9 4.9 21.1 12.0 15.7 1 1.0 39.1 13.0 
24 1.6 3.1 45.9 9.1 16.0 6.5 14.6 2.9 21.0 3.8 
48 1.1 1.3 18.3 1 1.0 2.4 2.1 7.2 5.0 3.8 2.6 
105,000 x g 
Microsomal 
fraction 10 4 0 2.1 0.9 5.8 6.9 8.1 7.2 7.5 1 1.0 
24 0.3 0.5 7.1 6.6 2.0 1.0 7.8 5.5 10.6 6.6 
48 0.3 0.5 1.1 1.1 0.5 0.6 
co 
ri 2.3 1.6 0.5 
50 4 0 4.8 1.3 11.6 3.1 9.0 7.7 36.3 21.0 
24 1.0 1.4 13.8 9.4 5.7 1.5 20.0 1 1.0 23.3 3.6 
48 0 1.1 1.1 1.5 2.8 6.6 9.2 3.7 2.0 
100 4 0 10.2 3.4 13.8 3.8 11.6 9.2 30.4 21.0 
24 1.1 1.1 23.4 17.0 10.3 2.8 19.6 9.8 22.3 6.5 
48 0 3.8 1.4 2.7 0.8 7.4 10.0 7.8 6.9 
aMean squared radius of induration. 4 animals/group 
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Table 4. Cutaneous reactivity in guinea pigs infected with Cryptococcus neoformans B551a and 
further tested with subcellular fractions of C. neoformans B-551 and 602 




Antigen Protein Hr 2 Wks. 3 Wks. 4 Wks. 5 Wks. 6 Wks. 
72 ±s.d. 72 ±s.d. 72 ±s.d. 72 ±s.d. 72 ±s.d. 
13,000 x g 
B 551 
PMS 10 4 5.4 6.0 5.7 1.3 6.5 2.9 0.8 1.3 7.9 6.9 
24 9.7 5.9 9.3 3.9 5.8 4.4 4.6 3.9 15.3 4.6 
48 2.8 2.1 2.1 3.0 1.3 2.5 1.5 1.8 9.9 4.9 
50 4 4.4 3.0 11.3 4.0 12.6 9.3 5.0 6.0 10.5 8.7 
24 9.1 6.2 28.0 8.5 13.5 6.2 13.0 11.0 16.0 1.6 
48 0.8 1.5 6.2 8.2 7.8 8.5 3.5 4.0 9.7 4.2 
100 4 4.0 3.5 8.5 3.1 8.3 7.0 6.8 5.0 13.8 12.0 
24 18.1 7.1 21.8 6.7 14.7 7.2 17.5 15 17.3 9.0 
48 10.4 8.3 10.4 12.0 6.4 2.1 5.9 7.6 8.2 3.1 
105,000 x g 
Supernatant 10 4 4.8 2.6 8.9 11.0 4.8 3.6 0.8 1.5 16.7 13.0 
24 14.7 7.4 19.2 22.0 11.9 1.7 11.2 6.3 20.9 8.2 
48 3.9 5.0 8.7 13.0 4.4 4.4 2.8 3.3 10.9 4.3 
50 4 9.0 7.4 14.0 5.8 11.7 3.7 13.5 8.1 18.6 15.0 
24 20.9 12.0 32.1 14.0 20.6 6.5 27.1 5.7 24.1 11.0 
48 26.8 11.0 23.9 4.1 6.4 2.3 10.4 6.7 11.1 2.1 
100 4 14.9 5.6 12.9 4.0 22.3 6.0 14.6 1.8 14.3 11.0 
24 35.2 11.0 32.7 7.2 20.8 9.7 28.1 8.9 20.4 4.1 
48 21.7 12.0 17.4 6.1 9.8 4.6 12.8 6.6 11.5 2.2 
105,000 x g 
Microsomal 
fraction 10 4 2.7 2.4 6.3 1.4 4.0 2.1 2.5 3.6 4.8 3.8 
24 6.3 4.2 18.8 4.9 3.6 2.2 5.1 3.8 6.9 0.7 
48 1.9 1.5 6.1 1.8 1.8 0.9 2.9 0.8 4.3 1.0 
50 4 5.8 2.2 11.5 2.8 8.1 4.5 10.8 3.8 10.1 6.8 
24 9.1 4.1 23.2 1.2 11.8 5.7 22.7 4.3 19.8 8.5 
48 5.8 2.2 9.2 3.4 7.9 5.7 7.3 4.1 9.3 3.9 
100 4 8.0 4.3 9.2 3.4 10.0 5.9 12.0 3.0 8.1 6.0 
24 14.6 2.5 32.2 9.0 21.7 5.9 28.9 2.6 21.0 3.8 
48 3.4 1.2 7.8 3.2 8.7 5.8 8.1 2.9 8.4 2.4 
a 1 x 10s live yeast ip 
bMean squared radius of induration ± standard deviation, 4 animals/group 
cpost-infection 
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tested in this group. In all instances the reactions persisted 
at 48 hr, but were decreased. All three antigens gave positive 
reactions at 4 hr, but these were always lower than the 24 hr 
reactions. When the antigenic dose was lowered to 10/^g there 
was a reduction in peak responses for all three antigens, but 
positive reactions persisting at 48 hr were observed. 
The cutaneous reactions of animals injected with acap- 
sular neoformans 602 were positive at the first skin test, 
indicating that acapsular cells were also stimulatory (Ta¬ 
ble 5) . The peak of reactivity for C. neoformans 602 sensitized 
animals was between week 4 and 5, compared with week 3 for those 
sensitized with B551. Overall reactivity to all three antigens 
in 602 sensitized animals were lower than in those receiving an 
equivalent dose of encapsulated (B551) cells. The m antigen 
was the most potent elicitor of 24 and 48 hr reactions in this 
group of animals. At the 50/4 g dose, reactions to all three 
antigens in this group were evident at 4 hr, reached a peak at 
24 hr and were present but reduced at 48 hr. Positive, but 
lesser reactions, were evoked by 10 g doses of these antigens. 
Animals injected i.p. with H_^ capsulatum A811 or albicans 
3181A and skin tested 4 weeks later were unresponsive to all 
concentrations of the JUs and 105K fractions. These data are 
depicted graphically for all three antigens at the 50/4g dose 
in Fig. 12-14. 
Lymphocyte transformation 
Skin test responses of infected guinea pigs reached a peak 
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Table 5 Cutaneous reactivity in guinea pigs sensitized with live Cryptococcus 
neoformans 602a and further tested with subcellular fractions of 
C. neoformans B-5SI and 602 
Cutaneous reactivity, mean ± standard deviation*1 
Time Elapsed 
Dose;pg 
Antigen of Protein Hr 2 Wks 3 Wks 4 Wks 5 Wks 6 Wks 
V ±s.d. V ±s.d. 72 ±s.d. 
— 2 r ±s.d. 
— 2 r ±s.d. 
B-551 10 4 1.8 3.0 3.9 1.4 11.1 2.1 8.0 6.9 7.2 3.1 
13,000 x g 24 0.4 0.8 5.5 3.4 9.6 3.1 5.8 8.5 6.4 2.8 
PMS 48 0.3 0.5 0.3 0.5 0.8 0.9 1 .3 1.9 2.7 0.9 
50 4 3.2 3.8 5.7 1.3 14.7 7.2 11.9 7.2 11.2 3.8 
24 2.0 2.5 8.2 5.1 12.1 3.7 14.1 7.8 13.0 4.4 
48 0.5 0.6 2.0 1.7 0 3.9 3.2 6.1 1.8 
100 4 3.2 5.0 10.2 4.6 15.1 6.8 14.5 8.1 13.2 2.3 
24 4.8 6.6 14.7 7.3 12.2 7.4 17.7 10.6 18.5 6.5 
48 2.9 2.3 2.2 1.8 3.2 5.0 4.7 3.3 7.8 3.2 
105,000 x g 10 4 1.6 3.1 5.2 1.8 9.3 3.9 7.9 6.9 9.2 4.6 
Supernatant 24 2.1 2.8 5.8 4.3 6.7 3.7 5.8 8.5 7.8 3.2 
48 0.3 0.5 0.8 1.5 0 1.3 1.9 3.7 1.0 
50 4 6.5 3.2 7.2 5.2 16.6 9.7 12.1 4.4 9.3 3.9 
24 8.0 4.1 9.8 7.2 13.2 8.6 12.2 5.5 17.6 2.0 
48 2.4 1.2 5.4 4.0 6.3 3.4 3.6 3.8 7.1 2.4 
100 4 10.6 5.3 11.4 1.8 15.7 7.0 13.8 7.5 11.2 3.7 
24 16.8 7.3 1 1.9 5.5 8.8 8.4 14.3 7.5 19.3 3.9 
48 13.1 7.7 6.3 1.9 4.2 3.4 5.6 2.5 14.7 3.2 
105,000 x g 10 4 1.6 0.6 5.2 1.8 4.7 1.8 6.0 1.2 3.1 0 
Microsomal 24 3.7 3.1 6.8 4.6 8.0 1.3 6.3 1.0 5.2 3.6 
fraction 48 3.4 2.3 3.5 2.6 1.7 1.0 3.6 3.1 0 
50 4 4.8 1.1 7.1 2.6 9.1 4.9 9.9 2.6 6.0 1.2 
24 7.2 3.4 8.6 3.6 9.0 3.6 14.0 7.3 13.9 4.7 
48 4.8 1.1 4.5 2.1 1.6 1.3 4.3 3.8 5.0 2.3 
100 4 bo
 
2.2 10.0 3.4 8.6 6.3 10.7 2.7 9.5 2.6 
24 11.8 8.5 13.0 5.0 12.0 3.6 17.8 4.9 16.2 4.3 
48 5.2 4.8 9.2 12.0 2.6 1.2 6.2 3.2 4.8 0.5 
aIXI07 live yeast 
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Time elapsed, weeks 
Fig. 12. Skin tests with the 105K antigen at the 50,Mg dose. 
Guinea pigs sensitized with 1 x ICT neoformans 
B551, t ; sensitized with 1 x 10^ acapsular C. 
neoformans 602, ■ ; sensitized with antigen and no 
live yeast, • . Results are expressed as mean square 

































1 i 1 i r 
2 3 4 5 6 
Time elapsed, weeks 
Fig. 13. Skin tests with the microsomal antigen (us) at the 
50ji g dose. Guinea pigs sensitized with 1 x 107 live 
C. neoformans B551, A ; sensitized with 1 x 107 
acapsular C. neoformans 602, ■ ; sensitized with 
antigen and no live yeast, • . Results are expressed 
as means squared radii of induration after 24 hr for 
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2 3 4 5 6 
Time elapsed, weeks 
Fig. 14. Skin tests with the PMS antigen at the 50ydg dose. 
Guinea pigs sensitized with 1 x 10? live C. neo- 
formans B551, à ; sensitized with 1 x 10^ acapsular 
C. neoformans 602, ■ ; sensitized with antigen and no 
live yeast, •. Results are expressed as mean squared 
radii of induration after 24 hr for four animals per 
group. 
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of activity between the third and fifth weeks. This period was 
a guide for priming animals for the lymphocyte function test. 
Animals were injected with 1 x 10^ live neoformans B551 and 
were boosted with antigens following the outline in "Materials 
and Methods." The total antigenic load of 105K antigen over the 
priming period was 600 g of protein per animal and for the us 
antigen, 1200 g. Both £|s and 105K fractions elicited blasto¬ 
génie responses in the PEC population (Table 6) . The optimal 
antigenic doses were 1 )A g/ml for ^ (0.25 /<g/culture) and 
10 g/ml (2.5jug/culture) for 105K. Four-day cultures were 
active, but after 6 days in culture, the stimulation ratios 
obtained were sharply reduced, probably due to exhaustion of 
the medium. 
The fetal calf serum supplement showed no additional 
benefit in the PEC responses compared with those obtained in 
serum-free medium. At the concentrations used, neither antigen 
was mitogenic nor toxic towards PEC. The 105K fraction tended 
to be toxic at the higher doses in the spleen cell cultures 
(Table 7) . PEC and PBL from three normal animals did not 
respond to these antigens in vitro. Optimal mitogenic re¬ 
sponses were elicited by ConA at the 2.5 p. g/ml dose. The 
splenocytes, obtained from 9 infected animals in 3 experiments, 
and lymph node cells from 4 animals were unresponsive to 
stimulation by either antigen over the range of experimental 
conditions (Table 8). Both splenocytes and lymph node cells 
responded vigorously to ConA (Tables 9-10). 
Table 6. (Expt. 118) Lymphocyte blastogenesis of peritoneal exudate cells elicited in vitro by subcellular 
fractions of C. neoformonsa in guinea pigs primed by infection6 and skin testingc 




of Protein/ml CPMf 
+ FCSd 
±S.d.9 S/Ch CPM 
SFe 
±S.d. S/C CPM 
+ FCS 
±S.d. S/C CPM 
SF 
±S.d. S/C 
1 (-) 0 1878 475 1.00 409 116 1.00 497 276 1.00 224 49 1.00 
fis 0.01 2703 512 1.44 642 277 1.57 398 90 0.80 222 38 1.00 
0.1 3063 286 1.63 1254 697 3.07 494 168 0.99 225 40 1.00 
1 4707 423 2.51 2909 1378 7.1 1 857 212 1.73 360 64 1.61 
10 2568 300 1.37 1872 459 4.58 514 62 1.04 357 267 1.59 
105K 0.1 2860 599 1.52 967 167 2.36 645 97 1.30 188 73 0.84 
1 3759 529 2.00 413 N.D. 1.01 483 112 0.98 224 17 1.00 
10 3629 36 1.93 1823 963 4.46 482 29 0.97 230 12 1.03 
2 (-) 0 2472 670 1.00 2709 44 1.00 1493 387 1.00 1638 102 1.00 
fis 0.01 3556 301 1.44 2247 628 0.83 1791 632 1.20 2682 910 1.64 
0.1 9265 843 3.75 9255 322 3.42 1576 307 1.05 2313 745 1.41 
1 20123 75 8.14 18475 7183 6.82 3702 1088 2.48 8329 1 12 5.08 
10 10142 686 4.10 14220 1187 5.25 4193 511 2.81 7367 1513 4.50 
105 K 0.1 7112 1509 2.88 7320 398 2.70 1780 657 1.19 1803 435 1.10 
1 1 1450 3132 4.63 1890 N.D. 0.70 1420 44 0.95 3937 1854 2.40 
10 20100 1585 8.13 905 N.D. 0.33 2741 512 1.83 7134 588 4.35 
(Cont’d) 
Table 6. (cont’d) Expt. 118 Antigen elicited blastogenesis of peritoneal cells 
(-) 0 15560 N.D.' 1.00 1630 831 1.00 27469 N.D. 1.00 6081 N.D. 1.00 
/US 0.01 3304 N.D. 0.21 6279 2300 3.85 12348 16052 0.45 26178 N.D. 4.30 
0.1 28770 N.D. 1.85 39923 5348 24.49 50484 10716 1.84 33108 N.D. 5.44 
1 7357 N.D. 1.85 60964 1951 37.40 47547 6315 1.73 13811 N.D. 2.27 
10 43518 N.D. 2.80 54801 3879 33.62 34195 1970 1.24 14435 N.D. 2.37 
105 K 0.1 26911 N.D. 1.73 15484 12378 9.50 36726 31888 1.34 42271 N.D. 6.95 
1 7689 N.D. 0.49 22740 10106 13.95 13863 17720 0.50 31304 N.D. 5.15 
10 49984 N.D. 3.21 17919 9134 10.99 16168 10315 0.59 8596 N.D. 1.41 
(-) 0 279 98 1.00 1715 219 1.00 592 219 1.00 1205 308 1.00 
/iS 0.01 356 81 1.27 4286 2101 2.50 1001 503 1.69 2283 922 1.89 
0.1 2233 555 7.99 6012 406 3.51 1829 370 3.09 966 179 0.80 
1 10749 429 38.53 13738 1294 8.01 4896 752 8.27 2123 448 1.76 
10 8157 423 29.24 2163 56 1.26 1854 289 3.13 1312 238 1.09 
105 K 0.1 386 36 1.38 3142 381 1.83 777 189 1.31 1803 395 1.50 
1 1589 80 5.70 6492 1168 3.79 1222 802 2.06 693 74 0.58 
10 4017 414 14.38 47664 6712 27.79 1496 514 2.53 333 N.D. 0.28 
aC. neoformans 602: 105 K = 105,000 x g supernatant and MS = 
microsomal fraction 
bl x 107 C. neoformans B-551 
cSee priming schedule, Table 
dFCS, fetal calf serum supplement (10%) 
eSF, serum free 
fCpm, counts/min, mean of triplicates 
aS.D., standard deviation 
hS/C, Cpm stimulated -r cpm control 
'N.D., not determined, duplicates 
Table 7. (Expt. 118) Lymphocyte blastogenesis of spleen cells elicited in vitro by subcellular fractions 
of C. neoformans3 in guinea pigs primed by infection15 and skintestingc 




of Protein/ml CPMf 
+ FCSd 
±S.d.9 S/Ch CPM 
SFe 
±S.d. S/C CPM 
+ FCS 
±S.d. S/C CPM 
SF 
±S.d. S/C 
(-) 0 1088 411 1.00 173 41 1.00 181 29 1.00 156 18 1.00 
1 MS 0.01 1210 620 1.11 153 0.58 0.88 400 191 2.21 98 26 0.63 
0.1 1340 237 1.23 198 67 1.14 399 N.D. 2.20 131 34 0.84 
1 812 105 0.75 164 26 0.95 201 N.D. 1.11 177 64 1.13 
10 199 39 0.18 72 6 0.42 148 57 0.82 171 83 1.10 
105 K 0.1 752 263 0.69 426 N.D. 2.46 278 181 1.54 125 57 0.80 
1 1028 N.D.' 0.94 104 13 0.60 277 247 1.53 90 38 0.58 
10 517 123 0.48 125 56 0.72 130 44 0.72 107 19 0.69 
2 (-) 0 320 35 1.00 331 26 1.00 210 26 1.00 436 11 1.00 
MS 0.01 377 100 1.18 648 96 1.96 211 24 1.01 645 98 1.48 
0.1 376 60 1.17 767 90 2.31 167 22 0.80 522 75 1.20 
1 380 67 1.19 581 29 1.75 245 100 1.17 334 3 0.77 
10 166 33 0.52 128 47 0.39 101 9 0.48 122 24 0.28 
105 K 0.1 369 7 1.16 869 79 2.62 182 15 0.87 974 194 2.23 
1 352 46 1.10 693 89 2.09 175 45 0.83 541 56 1.24 
10 265 78 0.83 133 10 0.40 92 16 0.44 77 11 0.18 
(Cont’d) 
Table 7. (cont’d) Expt. 118 Antigen elicited blastogenesis of spleen cells 
(-) 0 585 77 1.00 662 92 1.00 304 49 1.00 744 234 1.00 
MS 0.01 577 79 0.99 848 94 1.28 279 100 0.92 489 53 0.66 
0.1 670 147 1.15 946 119 1.43 285 15 0.94 498 203 0.67 
1 567 46 0.97 1145 142 1.73 320 34 1.05 435 44 0.58 
10 243 60 0.42 126 25 0.19 163 38 0.54 159 29 0.22 
105 K 0.1 554 112 0.95 1713 611 2.59 294 115 0.97 579 168 0.78 
1 628 60 1.07 1149 244 1.73 265 54 0.87 686 148 0.92 
10 321 60 0.55 251 57 0.38 183 65 0.60 182 19 0.24 
(-) 0 425 40 1.00 1059 232 1.00 217 106 1.00 680 117 1.00 
MS 0.01 307 15 0.72 1961 442 1.85 331 127 1.53 919 141 1.35 
0.1 414 11 0.97 1793 559 1.69 313 161 1.44 596 106 0.88 
1 366 16 0.86 672 457 0.63 223 27 1.03 376 75 0.55 
10 144 10 0.34 90 54 0.08 96 34 0.44 107 20 0.16 
105 K 0.1 N.D. N.D. N.D. 173 N.D. 0.16 274 46 1.26 1420 428 2.09 
1 543 85 1.28 512 798 0.48 253 26 1.17 529 41 0.78 
10 366 N.D. 0.86 601 858 0.57 172 45 0.79 74 16 0.11 
<Ti 
U> 
aC. neoformans 602: 105 K = 105,000 x g supernatant and MS = 
microsomal fraction 
bl x 107 C. neoformans B-551 
cSee priming schedule, Table 
dFCS, fetal calf serum supplement (10%) 
eSF, serum free 
fCpm, counts/min, mean of triplicates 
°S.D., standard deviation 
hS/C, Cpm stimulated -f cpm control 
'N.D., not determined, duplicates 
Table 8. (Expt. 118) Lymphocyte blastogenesis of lymph node cells elicited in vitro by subcellular fractions 
of C. neoformonsa in guinea pigs primed by infection6 and skin testing0 




of Protein/ml CPMf 
+ FCSd 
±S.d.9 S/Ch CPM 
SFe 
±S.d. S/C CPM 
+ FCS 
±S.d. S/C CPM 
SF 
±S.d. S/C 
1 (-) 0 199 35 1.00 197 135 1.00 451 391 1.00 93 17 1.00 
MS 0.01 177 55 0.89 105 36 0.53 347 75 0.77 76 4 3.60 
0.1 352 107 1.77 100 8 0.51 628 N.D. 1.39 51 9 0.55 
1 283 N.D. 1.42 141 55 0.71 208 73 0.46 54 8 0.58 
10 201 70 1.01 84 22 0.43 91 43 0.20 69 6 0.74 
105 K 0.1 372 142 1.86 75 3 0.38 579 86 1.28 148 9 1.59 
1 304 60 1.53 108 50 0.55 215 138 0.48 130 21 1.40 
10 179 36 0.90 104 41 0.53 102 14 0.23 92 25 0.99 
2 (-) 0 139 30 1.00 173 7 1.00 105 26 1.00 103 29 1.00 
Ms 0.01 123 37 0.89 67 16 0.39 238 31 2.27 51 11 0.50 
0.1 174 39 1.25 55 3 0.32 171 25 1.63 49 9 0.48 
1 168 6 1.21 107 63 0.62 118 23 1.12 69 16 0.67 
10 150 41 1.08 83 13 0.48 149 26 1.42 98 37 0.95 
105 K 0.1 198 31 1.42 129 10 0.75 120 29 1.14 133 72 1.29 
1 104 26 0.75 103 26 0.59 129 30 1.23 92 22 0.89 
10 92 15 0.66 69 12 0.40 109 6 1.04 74 29 0.72 
(Cont’d) 
Table 8. (cont’d) Expt. 118 Antigen elicited blastogenesis of lymph node cells 
(-) 0 930 197 1.00 242 74 1.00 1765 613 1.00 176 38 1.00 
Ids 0.01 1259 148 1.35 437 58 1.81 3212 1147 1.82 356 102 2.02 
0.1 1590 434 1.71 275 10 1.14 2400 636 1.36 345 76 1.96 
1 1805 438 1.94 186 34 0.77 2558 1160 1.45 97 15 0.55 
10 567 93 0.61 101 40 0.42 115 35 0.06 118 30 0.67 
105 K 0.1 1908 86 2.05 541 79 2.24 1907 643 1.08 412 40 2.34 
1 1454 304 1.56 266 72 1.10 1095 486 0.62 258 71 1.46 
10 763 82 0.82 148 46 0.61 253 37 0.14 155 49 0.88 
(-) 0 119 37 1.00 119 36 1.00 112 10 1.00 156 47 1.00 
Ids 0.01 217 42 1.82 59 12 0.50 137 32 1.22 44 9 0.28 
0.1 196 29 1.64 51 4 0.43 115 24 1.03 45 9 0.29 
1 193 N.D.' 1.62 73 3 0.61 84 33 0.75 61 14 0.39 
10 148 17 1.25 89 33 0.75 111 56 0.99 142 45 0.91 
105 K 0.1 160 80 0.83 73 42 0.61 168 31 1.50 106 32 0.68 
1 139 5 0.72 87 8 0.73 139 35 1.24 84 27 0.54 
10 76 15 0.64 72 20 0.60 91 66 0.81 68 4 0.44 
<Ti 
U1 
aC. neoforrmns 602: 105 K = 105,000 x g supernatant and yus = 
microsomal fraction 
bl x 107 C. neoformans B-551 
cSee priming schedule Table 
dFCS, fetal calf serum supplement (10%) 
eSF, serum free 
fCpm, counts/min, mean of triplicates 
9S.D., standard deviation 
hS/C, Cpm stimulated t- cpm control 
'N.D., not determined, duplicates 
Table 9. (Expt. 118) Lymphocyte blastogenesis (S/C)a of lymph node cells elicited in vitro by con A 
as a function of age of culture, source of lymphocytes and presence of serum supplement in the medium 






±S.d.e S/C CPM 
SFC 
±S.d. S/C CPM 
FCS 
±S.d. S/C CPM 
SF 
±S.d. S/C 
1 0 274 37 1.00 173 50 1.00 195 N.D.
f 1.00 383 59 1.00 
2.5 5306 N.D. 19.36 3357 3646 19.41 2591 N.D. 13.29 N.D. N.D. N.D. 
10 81229 17678 296.10 239 140 1.38 12988 N.D. 56.61 106 21 0.28 
40 75139 28108 273.90 165 92 0.96 8115 N.D. 41.62 178 66 0.46 
2 0 162 43 1.00 338 29 1.00 91 22 1.00 516 52 1.00 
2.5 3413 314 21.11 118 29 0.35 330 46 3.63 155 21 0.30 
10 5162 3865 31.93 115 33 0.34 3007 1201 33.04 209 49 0.41 
40 1385 340 8.56 123 35 0.36 281 54 3.09 296 97 0.57 
3 0 1171 133 1.00 369 64 1.00 1343 18 1.00 404 38 1.00 
2.5 45319 29379 38.69 18725 2165 50.74 14192 24 10.57 786 N.D. 1.95 
10 94182 53418 80.41 391 61 1.06 25500 2140 18.99 217 25 0.54 
40 15781 1542 13.47 205 83 0.55 2722 N.D. 2.03 216 64 0.53 
4 0 247 21.73 1.00 261 82 1.00 116 24 1.00 326 30 1.00 
2.5 1772 1311 7.18 67 4 0.26 117 9 1.01 109 10 0.34 
10 3737 N.D. 15.13 59 6 0.22 7835 1972 67.54 126 45 0.39 
40 3243 1581 13.15 99 41 0.38 149 18 1.28 252 78 0.77 
a(S/C); cpm stimulated -r cpm control 
bFCS; fetal calf serum (10%) 
CSF; serum free 
dCpm; counts/min 
eS.d.; standard deviation 
fN.D.; not determined, duplicates 
Table 10. (Expt. 118) Lymphocyte blastogenesis (S/C)a of spleen cells elicited in vitro by 
con A as a function of age of culture, source of lymphocytes and presence of serum supplement in the medium 






±S.D. S/C CPM 
SFC 
±S.D. S/C CPM 
+ FCS 
±S.D. S/C CPM 
SF 
+S.D. S/C 
1 0 1452 659 1.00 195 N.D.f 1.00 199 6 1.00 319 40 1.00 
2.5 5014 1326 3.45 N.D. N.D.f N.D. 1606 990 8.08 165 20 0.52 
10 33882 19269 23.34 663 N.D.f 3.39 5935 5505 29.87 122 10 0.38 
40 31425 3400 21.65 291 N.D.f 1.12 2057 2252 10.35 168 29 0.53 
2 0 496 189 1.00 343 N.D. 1.00 252 79 1.00 1268 278 1.00 
2.5 34694 9008 69.90 N.D. N.D. N.D. 6514 1534 25.82 17250 1585 13.61 
10 42785 4667 86.20 20050 N.D. 58.45 40987 7217 162.43 602 198 0.47 
40 3085 400 6.21 897 N.D. 2.62 1442 835 571 251 58 0.20 
3 0 639 52 1.00 312 N.D. 1.00 317 109 1.00 745 24 1.00 
2.5 12262 4574 19.18 N.D. N.D. N.D. 4966 2697 15.68 8233 940 11.05 
10 27358 5119 42.70 10756 N.D. 34.47 16888 616 53.33 753 147 1.01 
40 4576 1354 7.16 1261 N.D. 4.04 1043 227 3.29 235 31 0.31 
4 0 509 89 1.00 360 N.D. 1.00 292 64 1.00 1772 608 1.00 
2.5 3713 1904 7.30 N.D. N.D. N.D. 1812 310 6.21 1849 351 1.04 
10 17244 3152 33.90 7858 N.D. 21.83 6987 1516 23.93 936 117 0.53 
40 3173 1456 6.24 2187 N.D. 6.08 771 274 2.64 228 35 0.13 
a(S/C); cpm stimulated T cpm control 
bFCS; fetal calf serum (10%) 
CSF; serum free 
dCpm; counts/min 
8 S.d.; standard deviation 
<N.D.; not determined, duplicates 
68 
The PEC from five guinea pigs, primed with capsular poly¬ 
saccharide before being infected with live cryptococci, re¬ 
sponded to both antigens at all doses supplied after 4 days in 
culture (Table 11). Maximal stimulation ratios towards the jus 
antigen occurred at 1 pg per ml and the mean value ± s.d. for 
the group (4 day cultures with FCS) was 6.69 + 5.31, compared 
with a mean value of 9.39 + 11.75 for the previous experiment 
where priming with polysaccharide was not done. The difference 
between these two groups was not significant. The mean stimu¬ 
lation ratio obtained with 10/ig/ml of 105K antigen of PEC of 
polysaccharide-primed group was 9.01 + 9.84 (4 day cultures 
with FCS) compared with 8.55 + 8.97 in the previous group that 
did not receive polysaccharide. Thus, owing to the large 
animal-to-animal variation, differences betwen the stimulation 
ratios of the two groups could not be measured. Splenic 
lymphocytes of animals primed with capsular polysaccharide 
were unresponsive to the subcellular antigens (Table 12) . This 
was also consistent with the previous experiment. PBL from two 
out of four polysaccharide-primed guinea pigs responded to the 
jwe antigen with maximal stimulation ratios at the 1 per ml 
dose of 6.53 and 12.07 (4 day cultures with FCS) (Table 13) . Two 
of four animals, PBL tested with the 105K antigen, were re¬ 
sponders, with maximal stimulation at the ljug per ml dose [s/c, 
5.75, 19.59]. 
In the next experiment, the priming schedule was simpli¬ 
fied by using a single dose (4 to 5 x 107) Qf üve cryptococci, 
Table 11. (Expt. 119) Lymphocyte blastogenesis of peritoneal exudate cells elicited in vitro by 
subcellular fractions of C. neoformansa in guinea pigs pretreated with capsular 
polysaccharide prior to infection and skintestingc 




of Protein/ml CPMf 
+FCSd 
±S.d.9 S/Ch CPM 
SFe 
±S.d. S/C CPM 
+ FCS 
±S.d. S/C CPM 
SF 
+S.d. S/C 
1 (-) 0 1327 59 1.00 11360 2132 1.00 2561 295 1.00 5535 441 1.00 
MS 0.1 3387 448 2.55 36222 3908 3.19 2418 586 0.94 1061 660 0.19 
1 8695 2331 6.55 19617 4484 1.73 1042 618 0.41 8841 787 1.60 
10 6515 501 4.91 10812 254 0.95 1980 817 0.77 6608 112 1.19 
105K 0.1 7361 574 5.55 3039 2673 2.67 2423 478 0.95 1441 944 0.26 
1 10277 215 7.74 27334 5289 2.41 4738 N.D. 1.85 5209 185 0.94 
10 12586 165 9.48 23574 5960 2.07 1643 383 0.64 6539 377 1.18 
2 (-) 0 2350 322 1.00 2247 181 1.00 10231 443 1.00 5392 503 1.00 
MS 0.1 6117 N.D. 2.60 16415 4785 7.30 5425 87 0.53 4725 1075 0.88 
1 17112 3149 7.28 17439 401 7.76 6404 515 0.63 6742 1529 1.25 
10 21455 2429 9.13 17240 1140 7.67 7089 4235 0.69 9093 2036 1.69 
105K 0.1 5351 1085 2.28 5748 907 2.56 9122 2672 0.89 3217 2774 0.60 
1 9461 1638 4.02 11701 N.D. 5.21 5929 726 0.58 5586 1556 1.04 
10 16939 1676 7.21 15591 508 6.94 5034 679 0.49 5498 1855 1.02 
3 (-) 0 588 54 1.00 2632 344 1.00 321 109 1.00 6272 908 1.00 
MS 0.1 2346 257 3.99 7100 796 2.70 469 140 1.46 1475 168 0.24 
1 1477 199 2.51 9179 781 3.49 163 50 0.51 2535 330 0.40 
10 915 103 1.56 11794 456 4.48 180 56 0.56 2920 65 0.47 
105K 0.1 1903 621 3.24 15389 4719 5.85 809 71 2.56 5273 1200 0.84 
1 3349 151 5.70 5371 206 2.04 735 101 2.29 1580 504 0.25 
10 2497 275 4.25 4570 942 1.74 332 128 1.03 1016 581 0.16 
(cont’d) 
Table 11. (cont’d) Expt. 119 Antigen elicited blastogenesis of peritoneal exudate cells 
(-) 0 632 135 1.00 2942 1477 1.00 451 1 3561 1.00 4215 432 1.00 
Ms 0.1 6958 807 11.02 24664 3498 8.38 4060 1079 0.90 5675 1157 1.35 
1 9594 2006 15.19 26082 223 8.86 3199 1034 0.71 8428 1923 2.00 
10 5267 1118 8.34 2249 1736 0.76 1336 623 0.30 1355 514 0.32 
105K 0.1 8058 1031 12.76 16919 2233 5.75 6830 1422 1.51 3646 748 0.87 
1 14975 N.D. 23.69 2331 1 2385 7.92 9904 2438 2.20 4225 679 1.00 
10 11530 673 18.25 17232 955 5.86 8881 5914 1.97 5567 1179 1.32 
(-) 
MS 
0 374 88 1.00 1730 236 1.00 241 110 1.00 3801 462 1.00 
0.1 970 121 2.59 3319 204 1.92 243 49 1.01 549 80 0.14 
1 728 65 1.94 2542 245 1.47 214 54 0.89 844 85 0.22 
10 419 50 1.12 2226 214 1.29 217 44 0.90 908 137 0.24 
105K 0.1 1134 37 3.03 5009 1255 2.89 365 132 1.51 836 56 0.22 
1 968 70 2.59 3839 541 222 178 52 0.74 471 84 0.12 
10 933 55 2.49 918 1 10 0.53 147 43 0.61 506 27 0.13 
aC. neoformans 602: 105K = 105,000 X g supernatant and ps = microsomal fraction 
bl X 107 C. neoformans B-551 
cSee priming schedule, Table 
dFCS, fetal calf serum supplement (10%) 
eSF, serum free 
fCPM, counts/min, mean of triplicates 
9S.d.; standard deviation 
hS/C;Cpm stimulated cpm control 
Table 12. (Expt. 119) Lymphocyte blastogenesis of spleen cells elicited in vitro by 
subcellular fractions of C. neoformans3 in guinea pigs pretreated with capsular 
polysaccharide prior to infection and skintesting0 




of Protein/ml CPMf 
+FCSd 
±S.d.9 S/Ch CPM 
SFe 
±S.d. S/C CPM 
+FCS 
±S.d. S/C CPM 
SF 
±S.d. S/C 
1 (-) 0 521 101 1.00 225 18 1.00 N.D. N.D. N.D. 302 1 10 1.00 
MS 0.1 580 89 1.11 179 61 0.80 658 435 N.D. 238 55 0.79 
1 565 97 1.08 147 45 0.65 N.D. N.D. N.D. 111 10 0.37 
10 350 64 0.67 88 11 0.39 N.D. N.D. N.D. 185 N.D. 0.61 
105K 0.1 512 154 0.98 107 15 0.48 917 1023 N.D. 210 41 0.70 
1 497 17 0.95 121 65 0.54 724 630 N.D. 198 12 0.66 
10 353 26 0.68 147 63 0.65 437 437 N.D. 293 59 0.97 
2 (-) 0 1375 101 1.00 2951 549 1.00 N.D. N.D. N.D. 3958 2934 1.00 
MS 0.1 1439 170 1.05 2537 141 0.86 1215 469 N.D. 3289 325 0.83 
1 2103 375 1.53 1737 168 0.59 N.D. N.D. N.D. 3453 578 0.87 
10 1521 117 1.11 122 30 0.04 N.D. N.D. N.D. 177 36 0.04 
105K 0.1 1335 117 0.97 2400 731 0.81 1385 841 N.D. 4895 172 1.24 
1 1699 192 1.24 2446 178 0.83 1277 881 N.D. 3775 N.D. 0.95 
10 1086 230 0.79 431 46 0.15 752 454 N.D. 205 56 0.05 
3 (-) 0 569 121 1.00 842 89 1.00 N.D. N.D. N.D. 910 36 1.00 
MS 0.1 734 72 1.29 728 60 0.86 667 72 N.D. 888 26 0.97 
1 1499 359 2.63 795 98 0.94 N.D. N.D. N.D. 697 69 0.76 
10 799 55 1.37 116 51 0.14 N.D. N.D. N.D. 135 17 0.15 
105K 0.1 623 98 1.09 622 82 0.74 5114 204 N.D. 894 115 0.98 
1 653 191 1.15 539 126 0.64 458 40 N.D. 493 52 0.54 
10 460 64 0.81 230 72 0.27 281 21 N.D. 129 27 0.14 
(Cont’d) 
Table 12. (cont’d) Expt. 119 Antigen elicited blastogenesis of spleen cells 
(-) 0 1148 156 1.00 309 45 1.00 N.D. N.D. N.D. 230 97 1.00 
US 0.1 1003 172 0.87 228 60 0.26 709 792 N.D. 198 45 0.86 
1 907 93 0.79 105 33 0.34 N.D. N.D. N.D. 157 73 0.68 
10 473 92 0.41 131 46 0.42 N.D. N.D. N.D. 191 48 0.83 
105K 0.1 987 46 0.86 216 39 0.70 N.D. N.D. N.D. 116 31 0.50 
1 885 105 0.77 110 54 0.35 663 140 N.D. 157 22 0.68 
10 532 100 0.46 106 37 0.34 286 76 N.D. 162 36 0.76 
(-) 0 394 93 1.00 522 393 1.00 591 156 1.00 965 220 1.00 
/as 0.1 589 65 1.50 891 99 1.71 389 12 0.66 1102 160 1.14 
1 773 63 1.96 650 126 1.24 340 91 0.58 676 47 0.70 
10 460 50 1.17 109 55 0.21 334 109 0.57 123 27 0.13 
105K 0.1 536 14 1.36 797 202 1.53 709 128 1.20 1272 236 1.32 
1 544 112 1.38 768 61 1.47 557 206 0.94 991 50 1.03 
10 478 56 1.21 226 86 0.43 341 55 0.58 137 52 0.14 NJ 
aC. neoformans 602: 105K = 105,000 X g supernatant and /as = microsomal fraction 
bl X 107 C. neoformans B-551 
cSee priming schedule, Table 
dFCS, fetal calf serum supplement (10%) 
eSF, serum free 
fCPM, counts/min, mean of triplicates 
°S.d., standard deviation 
hS/C, Cpm stimulated 4- cpm control 
'N.D., not determined - super imposed 
Table 13. (Expt. 119) Lymphocyte blastogenesis of peripheral blood lymphocytes elicited in vitro by 
subcellular fractions of C. neoformansa in guinea pigs pretreated with capsular 
polysaccharide prior to infection and skintesting0 




of Protein/ml CPMf 
+FCSd 
±S.d.9 S/Ch CPM 
SFe 
±S.d. S/C CPM 
+FCS 
±S.d. S/C 
1 (-) 0 1291' N.D.' 1.00 N.D. N.D. N.D. 728 N.D. 1.00 
/JS 0.1 1339 N.D. 1.04 N.D. N.D. N.D. 1163 N.D. 1.60 
1 1837 N.D. 1.42 N.D. N.D. N.D. 1721 N.D. 2.36 
10 2967 N.D. 2.30 N.D. N.D. N.D. 1875 N.D. 2.58 
105K 0.1 1499 N.D. 1.16 N.D. N.D. N.D. 1207 N.D. 1.65 
1 2330 N.D. 1.80 N.D. N.D. N.D. 1239 N.D. 1.70 
10 2283 N.D. 1.77 N.D. N.D. N.D. 1085 N.D. 1.49 
2 (-) 0 182 N.D. 1.00 N.D. N.D. N.D. N.D. N.D. N.D. 
MS 0.1 912 N.D. 5.01 N.D. N.D. N.D. N.D. N.D. N.D. 
1 2196 N.D. 12.07 N.D. N.D. N.D. N.D. N.D. N.D. 
10 169 N.D. 0.99 N.D. N.D. N.D. N.D. N.D. N.D. 
105K 0.1 873 N.D. 4.80 N.D. N.D. N.D. N.D. N.D. N.D. 
1 3383 N.D. 19.59 N.D. N.D. N.D. N.D. N.D. N.D. 
10 113 N.D. 0.09 N.D. N.D. N.D. N.D. N.D. N.D. 
(Cont’d) 
Table 13. (cont’d) Expt. 119 Antigen elicited blastogenesis of peripheral blood lymphocytes 
(-) 0 3815 1455 1.00 2014 N.D. 1.00 2004 N.D. 1.00 
MS 0.1 2073 269 0.54 2277 N.D. 1.13 1459 N.D. 0.73 
1 4577 369 1.29 5016 N.D. 2.49 5646 N.D. 2.82 
10 4662 456 1.22 4403 N.D. 2.19 4590 N.D. 2.29 
105K 0.1 2008 454 0.53 2591 N.D. 1.29 1605 N.D. 0.80 
1 1892 44 0.50 3762 N.D. 1.87 2068 N.D. 1.03 
10 2712 2291 0.71 7972 N.D. 3.96 2984 N.D. 1.49 
(-) 0 1679 156 1.00 286
k N.D. 1.00 853 N.D. 1.00 
0.1 6494 1898 3.87 5437 N.D. 19.01 3398 N.D. 3.98 
1 10967 1188 6.53 5409 N.D. 18.91 16302 N.D. 19.11 
10 8774 1341 5.23 426 N.D. 1.49 6606 N.D. 7.75 
105K 0.1 3934 1526 2.34 4679 N.D. 16.36 942 N.D. 1.10 
1 9648 1294 5.75 5898 N.D. 20.62 5034 N.D. 5.90 
10 9393 643 5.59 2319 N.D. 8.11 6641 N.D. 7.79 
aC. neofonrums 602: 105K = 105,000 x g supernatant and MS = microsomal fraction 
bl x 107 C. ne oformans B-551 
cSee priming schedule, Table 
dFCS, fetal calf serum supplement (10%) 
eSF, serum free 
fCPM, counts/min, mean of triplicates 
9S.d., standard deviation 
hS/C, Cpm stimulated H- cpm control 





i.p., of a large capsule and also a small capsule isolate. No 
subsequent skin-testing, that might contribute to sensiti¬ 
zation, was done, and culture conditions were restricted to 4 
days with fetal calf serum. Animals were sacrificed after 4 
weeks. Cryptococci were recovered from the lung and spleen, but 
not from the brain of the 3 guinea pigs injected with the small 
capsule isolate, B551. The PBL and PEC obtained from two of 
three animals in this group responded to the antigen iri vitro 
(Table 14) . Animal No. 1 had vigorous PEC responses to both the 
jus and 105K antigens, and a brisk PBL response to the ^ys 
antigen. Animal No. 2 was unresponsive in the PEC, but showed 
a modest response to 105K antigen in the PBL population. The 
PBL of animal No. 3 expressed high responses to both antigens, 
but the PEC responses were low. 
In the group infected with a large capsule form, crypto¬ 
cocci were recovered from the spleen and lung of all three and 
from the brain of two out of three animals. (Table 15) . Animal 
No. 4 responded well in the PEC population to the jus antigen, 
but poorly to the 105K fraction. The PBL responses of this 
animal were only significant to/Us. Animal No. 5 was the most 
vigorous responder in this experiment. Cryptococci were not 
recovered from this animal's brain. Both antigens elicited 
high responses in the PBL, and had a significant response in the 
PEC toward the 105K antigen. 
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Table 14. Lymphocyte blastogenesis3 elicited by microsomal13 and 
soluble cytoplasmic antigens0 in guinea pigs infected with small capsule 




of Protein/ml CPM 
PBLe 
±S.d. S/C9 CPM 
PECf 
±S.d. S/C 
1 (-) 0 412 47 1.00 1862 530 1.00 
MS 0.1 601 181 1.46 7324 687 3.93 
1 2706 240 6.55 7482 1154 4.02 
10 875 213 2.12 3017 962 1.62 
105K 0.1 497 214 1.21 8202 465 4.40 
1 578 204 1.40 10627 150 5.71 
10 425 79 1.03 8139 261 4.37 
Con A 2.5 35.11 15.37 
2 (-) 0 384 24 1.00 1378 78 1.00 
MS 0.1 398 29 1.04 1202 80 0.87 
1 375 84 0.98 969 68 0.70 
10 507 179 2.84 550 64 0.40 
105K 0.1 311 62 0.81 1141 110 0.83 
1 423 60 1.10 972 249 0.70 
10 508 154 2.84 799 21 0.58 
ConA 2.5 70.83 20.92 
3 (-) 0 400 262 1.00 1882 163 1.00 
MS 0.1 5254 2008 13.14 2459 511 1.31 
1 12660 1728 31.65 2395 445 1.27 
10 510 28 1.28 1057 805 0.56 
105K 0.1 600 63 1.50 2233 380 1.19 
1 6057 755 15.14 4908 991 2.61 
10 5193 309 12.98 3912 249 2.08 
ConA 2.5 82.96 4.37 
^4 day cultures + 10% fetal calf serum 
“MS = microsomal fraction 
°105K = 105,000 x g supernatant 
5.08 x 101 yeast, i.p. 
PBL, peripheral blood leukocytes 
PKC, peritoneal exudate cells 
9S/C, ('pm stimulated : Cpm control 
N.D., not determined 
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Table IS.Lymphocyte blastogenesis3 elicited by microsomalb and 
soluble cytoplasmic antigensc in guinea pigs infected with large capsule 
Crvptococcus ncoformans 371A.d 
Animal 
No. Antigen 
Dose ; Mg 
of Protein/ml CPM 
PBLe 
±S.d. S/CB CPM 
PECf 
±S.d. S/C 
4 ( ) 0 245 73 1.00 747 130 1.00 
ps 0.1 360 152 1.47 1949 77 2.61 
1 693 262 2.83 5297 764 7.09 
10 826 254 3.37 5784 351 7.79 
I05KC 0.1 397 228 1.62 1689 237 2.26 
1 346 182 1.4! 1516 393 2.03 
10 343 64 1.40 1122 274 1.50 
Con A 25 61.18 11.67 
5 ( ) 0 865 37 1.00 727 212 1.00 
MS 0.1 10157 1225 1 1.74 581 1 705 7.99 
1 30637 2907 35.42 5233 1226 7.20 
10 4929 312 5.70 1164 66 1.60 
105K 0.1 5083 617 5.88 6116 1651 8.41 
1 1 5043 1519 17.39 7278 562 10.01 
10 10825 2093 12.51 5419 577 7.45 
Con A 25 89.09 4.72 
(i ( ) 0 324 1 1 1.00 891 254 1.00 
Ms 0.1 527 124 1.63 2421 337 2.72 
1 406 48 1.25 1749 210 1.96 
10 170 13 0.52 793 288 2.75 
I05K 0.1 251 55 0.77 2709 421 3.04 
1 323 92 1.00 4569 761 5.13 
10 365 100 1.13 4516 300 5.07 
Con A 25 19.87 2.61 
34 day cultures + 10% letal call'scrum 
b MS - microsomal fraction 
CI05K = 105.000 x p supernatant 
d4.3l x 107 yeast, i.p. 
3PBL, peripheral blood leukocytes 
PF.C, peritoneal exudate cells 




The main accomplishments of this research were in the 
areas of antigen fractionation and characterization and in the 
adaptation of the lymphocyte blastogenesis assay for studying 
cell-mediated responses in infected guinea pigs. The post- 
mitochondrial supernatant fraction developed by Hay and Reiss 
(1978) was further purified by ultracentrifugation. The re¬ 
sulting 105K soluble supernatant and microsomal fractions were 
potent and specific stimulants of delayed cutaneous hyper¬ 
sensitivity and in vitro lymphocyte blastogenesis. Hay and 
Reiss used an encapsulated yeast and showed that the capsular 
polysaccharide was present in the resulting antigen. This 
created a problem because this polysaccharide is a stimulant of 
immediate hypersensitivity of the Arthus type and as such is 
undesirable in an antigen dedicated to detecting cell-mediated 
immunity. This problem was overcome by using an acapsular 
mutant as the source of antigen. Although it could not be 
predicted beforehand, antigens prepared from the acapsular 
mutant were capable of evoking immune responses in animals 




Several problem areas were encountered that may form the 
basis of future studies. These will be discussed in the 
following sections. These problems involved the need for 
further fine structural analysis of the antigens and even more 
important, a better understanding of the regulation of immunity 
and immunological tolerance during infection. 
Preliminary Experiments 
Antigens first purified by DEAE Sephadex ion exchange 
column chromatography were toxic to both normal and anti¬ 
gen-sensitized animals during skin testing. This method of 
antigen preparation was abandoned because it refuted the ob¬ 
jectives of this research by eliciting responses in both normal 
and sensitized animals. 
A second and ultimately more successful approach was to 
prepare an antigen of a postmitochondrial supernatant obtained 
from the acapsular mutant, neoformans, by high speed differ¬ 
ential centrifugation. The ^4s fraction produced by this means 
consisted of particulates and could not be filter sterilized, 
but this was not found to a be a barrier to its use in in vitro 
lymphocyte blastogenesis assays. Thesis fraction had a high 
specific activity and 1 JJi g protein per ml was the optimal 
concentration for blastogenesis. Nonetheless, biochemically, 
this antigen was capable of further purification. 
The Microsomal Fraction 
Observation of the >|s fraction with the electron micro¬ 
scope showed that it contained ribosomes and cell membranes. 
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The state of preservation of the membranes was low, as might be 
expected from the mechanically disrupted cells and from the 
subsequent freeze-thawing necessary for storage at -40 C. The 
>ls fraction is of profound biological interest since it con¬ 
tained ribosomes in addition to cell membranes. Youmans and 
Youmans (1965) first showed, in the instance of mycobacteria, 
and more recently Tewari et al. (1978) showed with Histoplasma 
capsulatum, that ribosomes are stimulants to T-lymphocyte 
mediated immunity. The ribosomal components of the microsomal 
fraction may be responsible for the in vitro lymphocyte pro¬ 
liferation and this aspect requires future investigation. 
Membrane-bound glycoprotein and glycoside transferases were 
detected in the microsomal fraction of saprophytic cryptococci 
prepared by the same method used in the present research. 
Schutzbach and Ankel (1972) prepared a particulate (or micro¬ 
somal) enzyme complex of C^_ laurentii that catalyzed transfer 
14 of mannosyl and galactosyl residues from GDP-[ C] mannose and 
3 
UDP—[ H]-galactose to an endogenous glycoprotein acceptor. 
This glycoprotein was radiolabeled using endogenous enzymes 
and has several interesting properties that suggest a means of 
purification for the C_^ neoformans ps fraction. The glyco¬ 
protein is resistant to pronase which removes extraneous pro¬ 
tein. It can then be freed from membrane lipid by extraction 
with detergent and finally, because of its glycoside component, 
it can be bound and eluted from an immobilized lectin, Con- 
canavalin A. 
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Through the use of EM technique the ^ls antigen was shown 
to contain ribosomes. It is possible to further purify ribo¬ 
somes in order to investigate their contribution to the anti¬ 
genicity of this fraction. Youmans and Youmans (1965) mechan¬ 
ically ruptured cells of Mycobacterium tuberculosis with a 
pressure cell. The ruptured cellular mass was centrifuged at 
20,360 x g and the supernatant liquid was centrifuged at 
144,000 x g for 3 hr to obtain the cell free particulate 
fraction or ribosomal fraction. The ribosomal fraction showed 
only a slight capacity to immunize mice. When the ribosomal 
fraction was mixed with Freund incomplete adjuvant, the immu¬ 
nogenic activity was equivalent to the particulate fraction 
from which it was prepared. The ribosomal fraction was purified 
by treatment with sodium deoxycholate, dodecyl sulfate, and 1 M 
sodium chloride. The treated materials were centrifuged at 
144,000 x g, and the sediments were tested for immunogenicity 
both with and without the addition of Freund incomplete adju¬ 
vant. Without the adjuvant, the immunizing activities were 
very weak or absent; with the adjuvant, they were equivalent to 
that of the particulate fraction from which they were prepared. 
Thus, digestion of membranes with sodium dodecyl sulfate ef¬ 
fected a purification of ribosomes and the resulting prepara¬ 
tion could protect mice from challenge with the live agent. 
This method of purification has been studied and extended by 
Tewari et al. (1978) who should be consulted for a more current 
approach to preparation of ribosomal vaccines. 
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The 105,000 x g Supernatant Fraction 
After the 105K antigen was filter sterilized it did not 
lose the capacity to elicit delayed cutaneous responses. This 
antigenic fraction may be further purified under non-denatur¬ 
ing conditions by isoelectric focussing or by ion-exchange 
chromatography using a salt or pH gradient. The 105K fraction 
can be considered for human skin-tests and in vitro blasto- 
genesis if further studies will confirm its specificity and 
lack of toxicity. 
Suitability of Antigens for Skin Testing 
The us antigen, because of its particulate nature, is only 
suitable for in vitro tests. This is because it is not filter 
sterilized and there are objections to injecting particulate 
material into the skin. This antigen is a potent and specific 
elicitor of DCH and its in vitro correlate: lymphocyte blasto- 
genesis. The 105K and antigens are not ideal as skin test 
reagents in their present form because the experiments with 
guinea pigs showed that repeated skin testing induced a state 
of delayed hypersensitivity in normal noninfected guinea pigs. 
This stands in contrast to tuberculin and histoplasmin which do 
not induce hypersensitivity in persons who were not at some time 
exposed to the intact étiologie agent. Additional chemical 
modifications to reduce skin sensitizing activity are possi¬ 
ble. 
The presence of potent inducers DCH in the jjjs and 105K 
antigens suggests that their value may extend beyond reagents 
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for skin testing to a potential for use as vaccines. This 
aspect requires further investigation. 
Antigens prepared by differential centrifugation of the 
acapsular mutant were neither toxic nor mitogenic in normal 
guinea pigs, but they elicited positive DCH in infected guinea 
pigs. Normal animals apparently were unresponsive because 
their immune systems were not primed to recognize these anti¬ 
gens. On the second encounter, the normal guinea pigs responded 
2 
at 39.9 mm to the 50//g dose at 24 hr. 
Application of the Blastogenesis Assay for Human Use 
C. neoformans is generally distributed in the environ¬ 
ment, and yet the rate of cryptococcal meningitis is relatively 
low. About half of the patients with cryptococcal meningitis 
have some underlying immunodeficiency (See Literature Review). 
It would be of interest to know how the lymphocytes of crypto¬ 
coccosis patients with no known immunodeficiency respond to 
these antigens. They may have a subtle but specific lack of 
responsiveness to neoformans that may be genetically deter¬ 
mined . 
Another possible use for the blastogenesis assay in humans 
is to follow the patients during the course of amphotericin B 
therapy to find out if there is a regain of CMI functions when 
the infection comes under control. This information could 
provide a better understanding of clinical improvement and CMI 
in cryptococcosis patients. 
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Cell-Mediated Immunity in Cryptococcosis 
Guinea pigs infected with either C^ neoformans B551 or 602 
responded with good DCH to each antigen at the 50^g dose at 
24 hr, indicating that the acapsular mutant is a valid source 
of antigen for infections with other isolates of this fungus. 
The lymphocyte transformation assay using the 105K or jxs 
antigen offers an alternative to skin testing for surveying the 
level of immunity in normal people or among high risk indi¬ 
viduals, such as kidney transplant recipients. 
Diamond (1977) infected guinea pigs intraperitoneally 
with C^_ neoformans to study the effects of immunosuppression 
and immunostimulation in cryptococcosis. Female guinea pigs 
survived longer than the males, which was perhaps related to a 
greater capacity of the female monocytes to kill the crypto¬ 
cocci. As a means of immunosuppression, brief dosages of 
cortisone were given to the female guinea pigs which shortened 
their lives by depressing the immune response. The depression 
persisted along after the drug was stopped as indicated by the 
levels of cryptococcal polysaccharide in the peripheral blood. 
These levels were high enough to block the antibody response for 
several months after infection. Host resistance of the male 
0 
guinea pigs was stimulated by vaccinating them with 10 killing 
cryptococci in Freund complete adjuvant. Treatment with the 
adjuvant extended the survival by 120 days. 
Diamond and Bennett (1973) tested the ability of human 
peripheral blood lymphocytes to respond to killed yeast cells 
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of neoformans by in vitro incorporation of H thymidine. 
Lymphocytes from healthy patients with positive skin tests to 
C. neoformans had significantly higher stimulation ratios than 
cells from unexposed control subjects (negative skin tests). 
High levels of stimulation were also observed in some normal 
subjects with negative skin tests which might have occurred 
because the multiplicity of antigens contained in whole organ¬ 
isms may cross react with other microbes or because of the 
presence of nonspecific mitogen activity. Despite this high 
baseline of nonspecific stimulation in normal subjects, in 
vitro lymphocyte transformation stimulated by C_^ neoformans 
appeared to correlate with previous exposure determined by skin 
tests. The two groups of controls, exposed and unexposed, 
served as a frame of reference to evaluate the patients with 
cryptococcosis. Uptake of tritiated thymidine by lymphocytes 
from successfully treated patients with cryptococcosis was 
lower than that of exposed control subjects. Differences in 
unstimulated baseline controls were small for this technique 
and not statistically significant (1778.9 dpm + 552 in skin test 
positive controls, and 960 dpm + 152 in patients). Valentine 
(1971) has discussed the problem of such small nonimmunologic 
variations in baseline values and their influence on the 
reliability of the stimulation ratio. Depressed stimulation 
appeared to be specific for C^_ neoformans, as mean thymidine 
incorporation induced by streptokinase and streptodornase (SK- 
SD) in these two groups was not significantly different 
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(158,562 dpm in skin test-positive normals and 122,907 dpm in 
this group of patients) . Values for C^_ neoformans-induced 
uptake of thymidine in individual patients overlapped the range 
for skin test-positive normals. It is conceivable that pa¬ 
tients are a heterogeneous group, some with defective lympho¬ 
cyte transformation and some without, but the limited data 
presented cannot answer that point. There was no clear corre¬ 
lation between stimulation of lymphocytes and results of skin 
tests with the small number of patients surveyed. It is 
possible that with a more potent and specific antigen such as 
the 105K and the fractions a clearer picture would emerge 
about the status of cryptococcosis patients undergoing anti¬ 
fungal therapy. 
Graybill and Alford (1973) compared cell-mediated immune 
responses in patients who had recovered from cryptococcosis and 
healthy subjects. Cryptococcal patients were mildly lympho¬ 
pénie but showed no defects in the percentage of T-lymphocytes. 
Only one-third of the patients skin tested were positive to the 
400 and 1000 x g supernatant antigens and their reactions were 
less intense than healthy subjects (4 out of 12 patients had 
positive skin tests). One control subject out of 24 responded 
in the neoformans skin test. In contrast, few healthy 
subjects had positive transformation responses (9 out of 24 
subjects) to neoformans. One patient who was followed 
sequentially through treatment of cryptococcal meningitis ac¬ 
quired strong lymphocyte responses to neoformans. The drug 
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used for treatment was not specified. This study indicated that 
some patients with cryptococcosis have a degree of deficiency 
in cell-mediated responses to fungal antigens when a specific 
underlying process cannot be identified. 
The guinea pig splenocytes and lymph node lymphocytes were 
unresponsive in LTA but did respond to mitogens. If the 
splenocytes were in a state of tolerance induced by C^_ neo- 
formans growth in the spleen, the suppression was not so broad 
that it inhibited the mitogenic responses to ConA. It may be 
that the splenocytes were unresponsive in vitro, because as a 
result of infection these cells underwent blastogenesis in vivo 
and became exhausted or tolerant to the antigens. Immu¬ 
notolérance is a specific failure of the cellular or antibody 
immunological mechanisms to respond, induced by prior exposure 
to a given antigen. 
Splenocytes from mice sensitized with living, repeated 
injections of alive but avirulent mutant isolate of neo- 
formans were activated in vitro by whole, killed yeast (Fromt- 
ling et al., 1979). This showed that splenocytes are capable 
of blastogénie responses under certain conditions. 
Guinea pigs primed with a dose of cryptococcal poly¬ 
saccharide did not show any broad suppressions of blastogénie 
responses to the 105K or ^s antigens. Such suppression might 
be expected if the animals were in a state of immune paralysis 
analogous to that observed in mice primed with type III pneu¬ 
mococcal polysaccharide (Baker, 1975). 
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The organ involvement was to an extent dependent on the 
isolate of neoformans. The small capsule culture was 
recovered from spleen and the lung, but not from the brain in 
the three animals tested, but the large capsule culture was 
recovered from the brain and the other organs in two of the 
three animals. Staib et al. (1976) characterized the potential 
of 31 cryptococcal isolates for mice into three categories: 
those found only in brain; those found in organs other than the 
brain and high mortality isolates were completely dissemi¬ 
nated. Capsule thickness was not directly related to the extent 
of dissemination. There is need for additional studies to give 
more precise quantitation of the degree of dissemination. This 
could be accomplished by sacrificing animals at intervals early 
in the infection and counting colonies isolated from lung, 
spleen, kidney and brain. If this culture technique were 
combined with blastogenesis assays, the results could be an 
excellent method for monitoring the development of CMI during 
experimental infection. 
Animal to Animal Variation 
Guinea pigs used in this research were obtained from two 
different suppliers. The blastogénie indices that were deter¬ 
mined showed a large variation in responses between guinea 
pigs. This fact made comparisons from one experiment to the 
next difficult. In the future this variation could be reduced 
by using guinea pigs of a more standardized genetic background. 
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The standard experiment was to sacrifice the animals at 
the end of the priming period for a one-time analysis of each 
animal's lymphocyte responses. A better method could be 
developed whereby the animals would not be sacrificed but 
sufficient peripheral blood could be removed from the retro- 
orbital sinus of the eye for several sequential measurements of 
blastogenesis in the animals. This could result in reduced 
variability. It was not considered essential to quantitate the 
degree of infection in relation to LTA responses. It is now 
evident that correlation of the degree of infection with 
fluctuations in the lymphocyte responses will help to under¬ 
stand individual animal responses and could possibly reduce 
animal to animal variation in CMI measurements. 
CHAPTER VI 
SUMMARY AND CONCLUSION 
Antigen Preparation 
The antigens developed in this research elicited DCH and 
its in vitro correlate, lymphocyte blastogenesis in guinea pigs 
infected with C^ neoformans. This research extended earlier 
investigation by Hay and Reiss (1978) who prepared a post- 
mitochondrial supernatant fraction of C^ neoformans that had 
the ability to elicit delayed-type hypersensitivity and MIF 
production in infected mice. Thesis and 105K antigens prepared 
in the present research represented an improvement over the 
supernatant from disrupted yeast of C^ neoformans in the 
following ways: The antigens were obtained from an acapsular 
mutant so they lacked cryptococcal capsular polysaccharide. 
This was important because the polysaccharide is a stimulant of 
strong antibody-mediated 4 hr cutaneous reactions which con¬ 
fuses interpretation of DCH. Ultracentrifugation of the anti¬ 
gen at 105,000 x g localized the activity in a soluble, 
sterilizable supernatant fraction and a particulate, micro¬ 
somal fraction. Both of these antigens were specific and potent 
elicitors of blastogénie responses from PBL and PEC of infected 
animals. 
Skin Testing 
These antigens have proven to be specific for C^ neo¬ 
formans , because they show no crossreactivity in skin testing 
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of guinea pigs sensitized with Blastomyces dermatitidis or 
Histoplasma capsulatum. Skin tests of uninfected or control 
guinea pigs were negative after the first test, but repeated 
injections resulted in a rapid buildup of DCH. This is a 
disadvantage for a skin test reagent because repeated testing 
will lead to a conversion from negative to positive. Therefore, 
further modification is necessary if this reagent is to be 
suggested for human use. This could be accomplished by limited 
proteolysis, by heating, or by formalin treatment. In their 
present form these antigens may be investigated for their 
potential value as vaccines, since they seem to have the 
property of stimulating CMI. The j^s fraction was the most 
reactive antigen in animals infected with C. neoformans 602 and 
skin tested after 2 and 3 weeks, but the least reactive in 
animals infected with neoformans B551. More guinea pigs need 
to be tested to make this relationship clearer. 
Lymphocyte Transformation 
A single dose of live cryptococci is sufficient to sensi¬ 
tize lymphocytes which were removed from animals four weeks 
p. i. 
The PBL and PEC were responsive to each of the antigens (1 
to 10jug/ml) used in the LTA. The splenocytes and node lympho¬ 
cytes were unresponsive to either antigen during LTA. The unre¬ 
sponsiveness of these cells may have been due to their becoming 
tolerant to the antigens as a result of infection. 
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The 1Q5K antigen was filter sterilized and did not lose the 
capacity to elicit lymphocyte responses. This antigenic frac¬ 
tion may be further purified under non-denaturing conditions by 
isoelectric focussing or through the utilization of ion ex¬ 
change chromatography using salt or pH gradient. The j^s 
fraction consisted of membranes and ribosomes. Further puri¬ 
fication will be required to determine the contribution of each 
of these components to the total biological activity of the 
antigenic complex. The methods necessary to purify these 
fractions were discussed above. The value of these antigens to 
protect animals against subsequent challenge with live crypto¬ 
cocci is worthy of investigation because these antigens were 
potent stimulants of CMI. They may also be useful for testing 
lymphocyte responses of human patients with cryptococcosis and 
for surveys of exposure of persons in the environment and in 
high risk groups. 
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Instruments and Supplies for LTA 
Prior to LTA all equipment and supplies were cleaned and 
sterilized. Four guinea pigs were a manageable number of 
animals for a single LTA experiment. Twenty ml of mineral oil 
(Drakeol 6VR, Penreco Co., Butler, Pa.) was required for i.p. 
injections per animal and was autoclaved for 1 hr. The tissue 
culture medium used in harvesting the PEC and other lymphoid 
populations was RPMI 1640 with additions as listed in Materials 
and Methods. HBSS was used in its complete form (final 
concentration per liter) penicillin, 200 g/ml; streptomycin, 
100 g/ml; fungizone (Amphotericin B) , 2 g/ml; sodium bi¬ 
carbonate, adjusted to pH 7.2 - 7.4 by addition of sterile 7% 
(wt/vol) NaHC03 with a pH of 7.3 and osmolarity, 300. The an¬ 
tigen dilutions were prepared early in the day and stored in an 
ice bath. 
The equipment for each phase of this experiment was 
assembled in individual kits. For harvesting PBL the following 
supplies were needed: clippers, 70% ethanol, specimen jar, 
diethyl ether, six-30 ml syringes (containing 0.2 ml of 
phenol-free heparin, 1000 U.S.P. units per ml (Upjohn Company, 
Kalamazoo, Mich.), six-19 gauge needles, sufficient Falcon 
sterile centrifuge tubes (50 ml). For harvesting the PEC, a 
30 ml syringe fitted with one-13 gauge x 3 1/2 inch needle per 
animal for i.p. injection of the mineral oil. Other supplies 
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were hemostats (6"), scissors (4 inches sharp-sharp tips), 
forceps (rat-tooth, 4"), 70% ethanol, sufficient individual 
sterile pipets (5 and 10 ml), portable vacuum pump (adjust¬ 
able) , sufficient 500 ml side-arm vacuum flasks fitted with 
rubber stoppers and sterile rinsed latex tubing, ice bath, HBSS 
(cold) and a paper clip for removing cotton plugs from pipets. 
All scissors, hemostats, and forceps were stainless steel and 
were wrapped and sterilized in metal trays. The spleen har¬ 
vesting equipment contained sufficient 50 ml Falcon tubes with 
10 ml RMPI 1640 per tube. Also required were stainless steel 
screens, 3 inch diameter (60 mesh; Newark Wire Cloth Company, 
Newark, N.J.), syringe plungers (12 cc size) and petri dishes. 
Instrument Cleaning 
After each experiment all instruments were placed in metal 
discard pans containing diluted Amphyl disinfectant. The 
forceps, scissors and hemostats then were boiled for 30 min in 
a closed steam bath sterilizer. These instruments were ex¬ 
amined and cleaned of debris, rinsed in tap and then deionized 
water. They were oven dried for 1 hr at 100 C. Each type of 
instrument was placed into separate pans, wrapped in a towel, 
and sealed with sterilizer indicator tape. The pans then were 
autoclaved for 1 hr and stored until needed. 
The screens (60 mesh) were placed in an endotoxin-free 
discard pan, filled about one-third full with tap water con¬ 
taining solid detergent (Sparkleen, Fisher Scientific Co., 
Atlanta, Ga.) . The pan was autoclaved for 1 hr and then flushed 
105 
free of all tissue debris with tap water. Close checks were 
made to see if all debris was gone. Approximately 20 ml of the 
liquid detergent, 7X, (Linbro Scientific, Inc., Hamden, Conn.) 
was added to the pan, then it was filled with tap water and 
allowed to stand overnight. The screens then were flushed with 
tap water, with deionized water, and then placed in the oven for 
1 hr at 100 C. Each screen was wrapped separately in aluminum 
foil, then in a towel, sealed with indicator tape and steri¬ 
lized. 
